

## **Publications**

### **1985-1990**

1. Kuo HC, Tsai TC, Hsieh CY, Lee CJ. Voiding dysfunction after radical abdominal hysterectomy. J Formos Med Assoc 1985; 86:1137-46.
2. Kuo HC, Lin FS, Tsai TC. Endometriosis of the urinary bladder: Report of a case. J Formosan Med Assoc 1987; 86:1303-6.
3. Kuo HC, Tsai TC. The diagnostic value of urthral closure pressure profilometry in prostatic obstruction. J Formos Med Assoc 1987; 86:1202-9.
4. Kuo HC, Tsai TC. Assessment of prostatic obstruction and bladder function by urodynamic pressure flow study. J Formos Med Assoc 1987; 86:1084-92.
5. Kuo HC, Tsai TC. Idiopathic voiding dysfunction: A urodynamic basis of differential diagnosis. J Formos Med Assoc 1988; 87:1055-64.
6. Kuo HC, Tsai TC. Prostatism and prostatic size in the diagnosis of prostatic obstruction. J Surg Assoc ROC 1988; 21:273-81.
7. Yu HJ, Kuo HC. Evaluation of urdynamics for the diagnosis of female stress urinary incontinence. J Surg Assoc ROC 1988; 21:326-33.
8. Chang SC, Tsai TC, Kuo HC. Transrectal ultrasonography of the prostate. J Formos Med Assoc 1988; 87:1065-76.
9. Kuo HC, Tsai TC. Relationships of maximal flow rate, residual urine and bladder function in prostatic obstruction. J Surg Assoc ROC 1988; 21:165-73.
10. Kuo HC, Tsai TC. The predictive value of urine flow rate and voiding pressure in the operative outcome of benign prostatic hypertrophy. J Formos Med Assoc 1988; 87:323-30.
11. Chang SC, Kuo HC. Management of ureteral sone by ureteroscopy - a Tzu Chi general hospital experience. Tzu Chi Med J 1989; 1:11-9.
12. Kuo HC. Kock pouch as a continent urinary reservoir after total cystectomy - case report. Tzu Chi Med J 1989; 1:75-8.
13. Kuo HC. Neurogenic voiding dysfunction - classification urodynamic study. Tzu Chi Med J 1989; 1:3-10.
14. Chang HC, Kuo HC. Clinical application of transrectal sonography in the evaluation of stress urinary incontinence. J Urol ROC 1990; 1:11-6.
15. Chang HC, Chang SC, Kuo HC. Transrectal sonographic cystourethrography: studies in stress urinary incontinence. Urology 1990; 36:488-92.
16. Hsu T, Chang SC, Kuo HC. Clinical management of intrinsic ureterpelvic junction obstruction in infants and children. Tzu Chi Med J 1990; 2:20-6.
17. Chang HC, Kuo HC, Chiu TY, Tsai TC. Clinical application of transrectal sonographic voiding cystourethrography in male patients with voiding dysfunction. J Urol ROC 1990; 1:11-6.
18. Chang SC, Kuo HC. Continent ileal urinary diversion. J Urol ROC 1990; 1:34-9.
19. Kuo HC. Transrectal sonographic guided urethrotomy in treatment of severe urethral stricture - 3 cases

report. Tzu Chi Med J 1990; 2:31-5.

20. Yang SD, Kuo HC, Chang SC. Continent cystostomy - an alternative in the treatment of severe urethral rupture. Tzu Chi Med J 1990; 2:27-30.
21. Kuo HC, Hsu T, Chang SC. Urodynamic study as an aid in the diagnosis of interstitial cystitis. Tzu Chi Med J 1990; 2:464-72.
22. Hsu T, Chang SC, Kuo HC. Transtrectal ultrasonic cystourethrography in the evaluation of stress urinary incontinence. J Urol ROC 1990; 1:197-207.
23. Kuo HC, Hsu T, Chang SC. Predictive factors for successful operative outcome of benign prostatic hyperophy. Tzu Chi Med J 1990; 2:368-81.

## 1991-1995

24. Kuo HC, Hsu T, Chang SC. A new classification of female stress urinary incontinence-based on transrectal sonographic cystourethrography. J Formos Med Assoc 1991; 90:769-75.
25. Kuo HC. Complete duplication of ureter associated with ectopic ureteral orifice and genuine stress incontinence - a case report. Tzu Chi Med J 1992; 4:119-23.
26. Kuo HC, Chang SC, Hsu T. Urodynamic finding in interstitial cystitis. J Formosan Med Assoc 1992; 91:694-8.
27. Chang SC, Kuo HC, Hsu T. Transrectal ultrasound-assisted optic internal urethrotomy for management of complete obliteration of posterior urethra and bladder neck. J Endourol 1992; 6:377-82.
28. Kuo HC, Hsu T, Chang SC. DDAVP in the treatment of nocturnal enuresis - a double blind cross-over study. J Urol ROC 1992; 3:759-64.
29. Lee SP, Hsieh TS, Kuo HC. Can we predict recurrent urinary retention in benign prostatic hyperplasia patients? J Urol ROC 1992; 3:694-9.
30. Kuo HC, Chang SC, Hsu T. Can patients with detrusor areflexia regain voiding ability following prostatic surgery for urinary retention? Tzu Chi Med J 1992; 4:223-9.
31. Kuo HC, Hsu T, Chang SC. Treatment of neuropathic contracted bladder by ileal augmentation cystoplasty. Tzu Chi Med J 1992; 4:13-8.
32. Kuo HC. The urodynamic characteristics in various bladder reconstructions with a detubularized ileal segment. Tzu Chi Med J 1993; 5:153-62.
33. Liao YM, Kuo HC, Hsu T. Comparison of TUIP and TURP in the treatment of small benign prostates. Tzu Chi Med J 1993; 5:23-8.
34. Kuo HC, Hsu T, Chang SC. A modified non-incision non-buffer endoscopic bladder neck suspension for female stress urinary incontinence-surgical technique and its mid-term result. Tzu Chi Med J 1993; 5:251-7.
35. Chang SC, Liao YM, Hsu T, Kuo HC. Treatment of symptomatic simple renal cyst with ultrasound guided percutaneous aspiration and minocycline sclerotherapy: results and follow-up. J Urol Assoc ROC 1993; 4:112-3.
36. Chang SC, Hsu T, Kuo HC. Treatment options for upper ureteral calculi: a comparison between ureteroscopy and extracorporeal shock wave lithotripsy. Tzu Chi Med J 1993; 5:15-21.

37. Fang JS, Kuo HC, Liu CH. Metiotic study of infertility in men – A preliminary report. Tzu Chi Med J 1993; 5:83-91.
38. Chang SC, Ho CM, Kuo HC. Ureteroscopic treatment of lower ureteral calculi in the era of extracorporeal shock wave lithotripsy: form a developing country point of view. J Urol 1993; 150:1395-8.
39. Kuo HC. Clinical implication of rapid cystometry in urinary retention with a contractile detrusor. Tzu Chi Med J 1993; 5:183-9.
40. Kuo HC, Chang SC, Hsu T. Experience of external sphincterotomy in the treatment of detrusor external sphincter dyssynergia. Tzu Chi Med J 1993; 5:105-11.
41. Chang SC, Kuo HC, Hsu T. Extracorporeal shock wave lithotripsy for obstructed proximal urthelial stone. Eur Urol 1993; 24:177-84.
42. Kuo HC, Chang SC, Hsu T. Predictive factors for successful surgical outcome of benign prostatic hypertrophy. Eur Urol 1993; 24:12-9.
43. Kuo HC, Chang SC, Hsu T. Application of transrectal sonography in the diagnosis and treatment of female stress urinary incontinence. Eur Urol 1994; 26:77-84.
44. Kuo HC, Chang SC, Hsu T. Contractile properties of prostatic strips in different histological types of obstructive benign prostatic hypertrophy. Tzu Chi Med J 1994; 6:85-94.
45. Kuo HC. Treatment of hypersensitive bladder and interstial cystitis by intravesical instillation of capsaicin. Tzu Chi Med J 1994; 6:239-44.
46. Kuo HC. The urodynamic findings in normal females in Taiwan. Tzu Chi Med J 1994; 6:163-9.
47. Kuo HC. The effect of mild bladder outlet obstruction on rabbit urinary bladder structure and function. J Formos Med Assoc 1995; 94:555-61.
48. Ho CM, Chang SC, Kuo HC. Indwelling ureteral stent-induced bladder and ureteral stones - a case report. J Urol ROC 1995; 6:237-40.
49. Ho CM, Chang SC, Hsu T, Kuo HC. Primary adenocarcinoma of the renal pelvis: A case report. Tzu Chi Med J 1995; 7:217-21.
50. Ho CM, Hsu T, Chang SC, Kuo HC. Clinical applications of diuretic renosography in patients with ureteral trauma. Tzu Chi Med J 1995; 7:203-9.
51. Kuo HC. Urological management of spinal cord injuries in eastern Taiwan. Tzu Chi Med J 1995; 7:11-9.
52. Ho CM, Hsu T, Chang SC, Kuo HC. Renal trauma - a review of 13 cases. Tzu Chi Med J 1995; 7:293-300.
53. Kuo HC. Effects of capsaicin on detrusor contractility - a preliminary study in human and rat urinary bladders. Tzu Chi Med J 1995; 7:167-78.

## **1996-2000**

54. Kuo HC. Effects of capsaicin on detrusor contractiltiy of rats: An in vivo and isolated whole bladder study. Urol Int 1996; 57:51-7.
55. Kuo HC. Impact of age on the urodynamic parameters in the patients with symptomatic bladder outlet

obstruction. Tzu Chi Med J 1996; 8:197-203.

56. Ho CM, Chang SC, Hsu T, Kuo HC. Percutaneous antegrade rigid nephroscopic extraction of upper ureteral stone. J Urol ROC 1996; 7:200-4.
57. Kuo HC. The effect of intravesical capsaicin on detrusor contractility - a study of the concentration and duration in rat urinary bladders. Tzu Chi Med J 1996; 8:1-11.
58. Kuo HC. The effect of capsaicin on the contractility of human detrusor - an in vitro study in normal and spinal cord injury bladders. Proceedings International Continence Society 26th Annual Meeting, Athens, Greece, 1996, pp 93-8.
59. Kuo HC. Transrectal sonography of the female urethra in incontinence and frequency-urgency syndrome. J Ultrasound Med 1996; 15:363-70.
60. Ho CM, Hsu T, Chang SC, Kuo HC. Experience of transrectal voiding sonography and urodynamics in the evaluation of detrusor sphincter dyssynergia. Tzu Chi Med J 1996; 8:37-8.
61. Kuo HC. Recovery of bladder function after relief of mild outlet obstruction of different durations in rabbits. J Formos Med Assoc 1996; 95:469-73.
62. Kuo HC. Capsaicin effects on detrusor contractility in capsaicin desensitized rats but not the micturition reflex. J Formos Med Assoc 1996; 96:691-6.
63. Kuo HC. The uroflowmetry in normal men and after prostatectomy. Eur Urol 1997; 31:447-52.
64. Kuo HC. Clinical outcome and quality of life after enterocystoplasty for contracted bladders. Urol Int 1997; 58:160-5.
65. Kuo HC. Comparative study of the effects of capsaicin on the contractility of normal and spinal cord injured human bladders. Proceedings NSC Life Sciences 1997; 21:13-9.
66. Kuo HC. Inhibitory effect of capsaicin on detrusor contractility: further study in the presence of ganglionic blocker and neurokinin receptor antagonist in the rat urinary bladder. Urol Int 1997; 59:95-101.
67. Kuo HC. Reversibility of the inhibitory effect of intravesical capsaicin on the micturition reflex in rats. J Formos Med Assoc 1997; 96:819-24.
68. Kuo HC. Transitional zone index of the prostate as an indicator of bladder outlet obstruction and a predictor of response to medical treatment in symptomatic benign prostatic hyperplasia. Tzu Chi Med J 1997; 9:249-58.
69. Kuo HC. Capsaicin inhibits detrusor contractility but not the micturition reflex in capsaicin-desensitized rats. J Formos Med Assoc 1997; 96:691-6.
70. Kuo HC. Bladder autoaugmentation in treatment of neuropathic bladder dysfunction. Tzu Chi Med J 1997; 9:191-7.
71. Kuo HC. Comparative study of therapeutic effects of dibenylamine finasteride and combination drugs for symptomatic benign prostatic hyperplasia. Urol Int 1998; 60:85-91.
72. Kuo HC. Transrectal sonography investigation of urethral and paraurethral structures in women with stress urinary incontinence. J Ultrasound Med 1998; 17:311-20.
73. Kuo HC. Quality of life after active urological management of chronic spinal cord injury in eastern Taiwan. Eur Urol 1998; 34:37-46.
74. Kuo HC. Clinical prostate score for diagnosis of bladder outlet obstruction by prostate measurements

and uroflowmetry. *Urology* 1999; 54:90-6.

75. Kuo HC. Videourodynamic evaluation of the pathophysiology of lower urinary tract symptoms in neurologically intact women. *Tzu Chi Med J* 1999; 11:203-13.
76. Kuo HC. Videourodynamic results after pubovaginal sling procedure for stress urinary incontinence. *Urology* 1999; 54:802-7.
77. Kuo HC. Investigation of the Voiding Management of Chronic Spinal Cord Injured Patients in Taiwan. *Tzu Chi Med J* 1999; 11:69-78.
78. Kuo HC. The relationships of urethral and pelvic floor muscles and the urethral pressure measurements in women with stress urinary incontinence. *Eur Urol* 2000; 37:149-55.
79. Kuo HC. Pathophysiology of lower urinary tract symptoms in aged men without bladder outlet obstruction. *Urol Int* 2000;64:86-92.
80. Kuo HC. Videourodynamic study for diagnosis of bladder outlet obstruction in women. *J Formos Med Assoc* 2000; 99:386-92.
81. Kuo HC. Effectiveness of baclofen plus terazosin treatment in patients with lower urinary tract symptoms caused by spastic urethral sphincter. *Tzu Chi Med J* 2000; 12:141-8.
82. Kuo HC. Dysfunctional voiding in women with lower urinary tract symptoms. *Tzu Chi Med J* 2000; 12:217-24.
83. Lin SF, Tsai YF, Kuo HC, Yeh SH. Sexual function of men with spinal cord injury in Hualien. *Tzu Chi Med J* 2000; 12:59-65.
84. Kuo HC. The urological management of voiding dysfunction in chronic spinal cord injury. *J Rehab Med Assoc ROC* 2000; 28:195-211. (Review)

## 2001~2005

85. Kuo HC. Long-term results of surgical treatment for female stress urinary incontinence. *Urol Int* 2001; 66:13-7.
86. Kuo HC. Comparison of video urodynamic results after the pubovaginal sling procedure using rectus fascia and polypropylene mesh for stress urinary incontinence. *J Urol* 2001; 165:163-8.
87. Kuo HC. Anatomical and functional results of pubovaginal sling procedure using polypropylene mesh for the treatment of stress urinary incontinence. *J Urol* 2001; 166:152-7.
88. Kuo HC. Sonographic evaluation of anatomic results after the pubovaginal sling procedure for stress urinary incontinence. *J Ultrasound Med* 2001; 20:739-47.
89. Kuo HC. Urodynamic results of intravesical heparin therapy for women with frequency urgency syndrome and interstitial cystitis. *J Formos Med Assoc* 2001; 100:309-14.
90. Kuo HC. Clinical application of videourodynamics in diagnosis of lower urinary tract dysfunction. *Tzu Chi Med J* 2001; 13:1-21. (Review)
91. Kuo HC. The surgical results of the pubovaginal sling procedure using polypropylene mesh for stress urinary incontinence. *BJU Int* 2001; 88:884-8.
92. Kuo HC. Clinical assessment of pelvic floor hypertonicity. *J Urol ROC* 2001; 12:1-8. (Review)
93. Kuo HC. Efficacy of desmopressin in the treatment of refractory nocturia in the patients aged over 65

years. *Urology* 2002; 59:485-9.

94. Kuo HC. Analysis of the pathophysiology of the lower urinary tract symptoms in patients after prostatectomy. *Urol Int* 2002; 68:99-104.
95. Kuo HC. Effects of vaginal trauma and oophorectomy on the continence mechanism in rats. *Urol Int* 2002; 69:36-41.
96. Liu HT, Lin TH, Kuo HC, Vhen YC, Tsay HJ, Jeng HH, Tsai PC, Shie FK, Chen JH, Huang HB: Identification of the alternative splice products encoded by the human protein phosphatase inhibitor-1 gene. *Biochemical and Biophysical Research communication* 2002; 291:1293-6.
97. Kuo HC. Effect of botulinum A toxin in the treatment of voiding dysfunction due to detrusor underactivity. *Urology* 2003; 61:550-4.
98. Kuo HC. Videourodynamic analysis of the relationship of valsalva and cough leak-point pressures in women with stress urinary incontinence. *Urology* 2003; 61: 544-9.
99. Kuo HC. Videourodynamic results in stress urinary incontinence patients after pelvic floor muscle training. *J Formos Med Assoc* 2003; 102:23-9.
100. Kuo HC. Urodynamic study and potassium sensitivity test for women with frequency urgency syndrome and interstitial cystitis. *Urol Int* 2003; 71:61-5.
101. Kuo HC. Effectiveness of intravesical resiniferatoxin for anticholinergic treatment refractory detrusor overactivity to non-spinal cord lesions. *J Urol* 2003; 170:835-9.
102. Ho SC, Wang LY, Hong AI, Kuo HC. Intakes of high animal protein diets and urinary stone disease. *Tzu Chi Med J* 2003; 15:155-62. (Correspondence)
103. Kuo HC. Urodynamics and management of neurogenic voiding dysfunction. *Tzu Chi Med J* 2003; 15:205-21. (Review)
104. Kuo HC. Effectiveness of intravesical resiniferatoxin in treating detrusor Hyper-reflexia and external sphincter dyssynergia in patients with chronic spinal cord lesions. *BJU Int* 2003; 92:597- 601.
105. Kuo HC. Botulinum A toxin urethral injection for the treatment of lower urinary tract dysfunction. *J Urol* 2003; 170:1908-12.
106. Kuo HC. Urodynamic parameters for the diagnosis of bladder outlet obstruction in women. *Urol Int* 2004; 72:46-51.
107. Kuo HC. Urodynamic evidence of the effectiveness of botulinum A toxin injection in the treatment of detrusor overactivity refractory to anticholinergics. *Urology* 2004; 63:868-72.
108. Chen YH, Kuo HC. Botulinum A toxin treatment of urethral sphincter pseudodyssynergia in patients with cerebrovascular accidents or intracranial lesions. *Urol Int* 2004; 73:156-62. (Correspondence)
109. Peng CH, Kuo HC. Nitric oxide donor for urethral pressure profilometry in evaluation of urethral function in patients with voiding dysfunction. *Tzu Chi Med J* 2004; 16:211-6. (Correspondence)
110. Chen YH, Kuo HC. Correlation of the clinical diagnosis by three-day voiding diary and urodynamic results in patients with frequency urgency syndrome. *J Taiwan Urol Assoc* 2004; 15:103-8. (Correspondence)

111. Liao YM, Kuo HC. Clinical application of botulinum A toxin for lower urinary tract diseases. *Tzu Chi Med J* 2004; 16:349-57. (Correspondence) (Review)
112. Kuo HC. Long-term surgical results of pubovaginal sling procedure using polypropylene mesh in the treatment of stress urinary incontinence. *Urol Int* 2005; 74:147-52.
113. Peng CH, Kuo HC. Transurethral incision of bladder neck in treatment of bladder neck obstruction in women. *Urology* 2005; 65:275-8. (Correspondence)
114. Kuo HC. Prostate botulinum toxin A injection – an alternative treatment for benign prostatic obstruction in poor surgical candidates. *Urology* 2005; 65:670-4.
115. Chen YH, Kuo HC. Effects of tolterodine on lower urinary tract symptoms and voiding efficiency in Taiwanese patients with an overactive bladder. *JTUA* 2005; 16:7-12. (Correspondence)
116. Kuo HC. Multiple intravesical instillation of low-dose resiniferatoxin is effective in the treatment of detrusor overactivity refractory to anticholinergics. *BJU Int* 2005; 95:1023-7.
117. Kuo HC. Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics. *Urology* 2005; 66:94-8.
118. Kuo HC. Preliminary results of suburothelial injection of botulinum A toxin in the treatment of chronic interstitial cystitis. *Urol Int* 2005; 75:170-4.
119. Kuo HC. Neurogenic voiding dysfunction. *Formosan J Med* 2005; 9:482-8. (Review)
120. Kuo HC. Effectiveness of urethral injection of botulinum A toxin in the treatment of voiding dysfunction after radical hysterectomy. *Urol Int* 2005; 75:247-51.
121. Kuo HC. Practice point commentary. *Nature Clinical Practice Urology* 2005; 2:414-5.
122. Kuo HC. Videourodynamic characteristics and lower urinary tract symptoms of female bladder outlet obstruction. *Urology* 2005; 66:1005-9.

## 2006~2010

123. Kuo HC. Therapeutic effects of suburothelial injection of botulinum A toxin for neurogenic detrusor overactivity due to chronic cerebrovascular accident and spinal cord lesion. *Urology* 2006; 67:232-6.
124. Kuo HC, Liu HT. Investigation of dysfunctional voiding in children with urgency frequency syndrome and urinary incontinence. *Urol Int* 2006; 76:72-6.
125. LiaoYM, Kuo HC. Discontinuation of an alpha-1-blocker or 5- alpha- reductase inhibitor after combination medical treatment in patients with benign prostatic hyperplasia. *Tzu Chi Med J* 2006; 18:91-6. (Correspondence)
126. Kuo HC. Current therapeutic advances in chronic interstitial cystitis. *Tzu Chi Med J* 2006; 18:167-74. (Review)
127. Kuo HC, Liu HT, Yang WC. Therapeutic effects of multiple resiniferatoxin intravesical instillations in patients with refractory detrusor overactivity: a randomized, double-blind, placebo controlled study. *J Urol* 2006; 176:641-5.
128. Chen JL, Kuo HC. Implications of prostatic volume measurements on the degree of bladder

- outlet obstruction in men with benign prostatic hyperplasia and lower urinary tract symptoms. JUTA 2006; 17:41-7. (Correspondence)
129. Chen JL, Liao JH, Kuo HC. Immunochemotherapy in advanced renal cell carcinoma with bone metastasis. Tzu Chi Med J 2006; 18:299-303. (Correspondence)
  130. Chen YC, Kuo HC. A small pheochromocytoma of the urinary bladder with atypical symptom. Tzu Chi Med J 2006; 18:295-8. (Correspondence)
  131. Ke QS, Kuo HC. Synchronous ipsilateral renal cell and transitional cell carcinoma: A case report. JTUA 2006; 17:67-70. (Case report) (Correspondence)
  132. Ke QS, Kuo HC. Predictive factors for satisfactory long-term therapeutic outcomes in patients with interstitial cystitis. JUTA 2006; 17:93-9. (Correspondence)
  133. Kuo HC. Will suburothelial injection of small dose of botulinum A toxin have similar therapeutic effects and less adverse events for refractory detrusor overactivity? Urology 2006; 68:993-8.
  134. Chen DY, Kuo HC. Treatment of lower urinary tract symptoms and overactive bladder – focus on bladder sensory innervation. Tzu Chi Med J 2006; 18:333-44. (Correspondence) (Review)
  135. Kuo HC. Recovery of detrusor function after urethral botulinum A toxin injection in patients with idiopathic low detrusor contractility and voiding dysfunction. Urology 2007; 69:57-62.
  136. Peng CH, Kuo HC. Multiple intravesical instillations of low-dose resiniferatoxin in treatment of refractory interstitial cystitis. Urol Int 2007; 78:78-81. (Correspondence)
  137. Kuo HC. Effect of detrusor function on the therapeutic outcome of suburethral sling procedure using a polypropylene sling for stress urinary incontinence in women. Scand J Urol Nephrol 2007; 41:138-43.
  138. Chuang FC, Kuo HC. Correlation of bladder base elevation with pelvic floor hypertonicity in women with lower urinary tract symptoms. Neurourol Urodyn 2007; 26:502-6. (Correspondence)
  139. Kuo HC. Differential diagnosis of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and non-benign prostatic hyperplasia. Incont Pelvic Floor Dysfunct 2007; 1(Suppl 1):3-6. (Review)
  140. Liao YM, Kuo HC. Biofeedback pelvic floor muscle training for voiding dysfunction and overactive bladder. Incont Pelvic Floor Dysfunct 2007; 1:13-5. (Correspondence)
  141. Bih LI, Kuo HC. Chronic spinal cord injury with intractable urinary incontinence. Incont Pelvic Floor Dysfunct 2007; 1:17-8. (Case analysis)
  142. Hsu YH, Kuo HC. Histological changes in benign prostatic hyperplasia after botulinum toxin A injection. Incont Pelvic Floor Dysfunct 2007; 1:19. (Clinical pearl)
  143. Liu HT, Kuo HC. Increased nerve growth factor production in suburothelium in patients with chronic interstitial cystitis. Incont Pelvic Floor Dysfunct 2007; 1:20. (Clinical pearl)
  144. Kuo HC. Spastic urethral sphincter with bladder outlet obstruction in a woman. Incont Pelvic Floor Dysfunct 2007; 1:21. (Clinical pearl)
  145. Kuo HC. Urethral stricture and detrusor overactivity in a female stroke patient. Incont Pelvic

- Floor Dysfunct 2007; 1:22. (Clinical pearl)
146. Kuo HC. Detrusor overactivity with pseudodyssynergia and benign prostate obstruction in a male stroke patient. *Incont Pelvic Floor Dysfunct* 2007; 1:23. (Clinical pearl)
  147. Kuo HC. Detrusor sphincter dyssynergia in spinal cord injury. *Incont Pelvic Floor Dysfunct* 2007; 1:24. (Clinical pearl)
  148. Kuo HC. Shrinkage of prostate glands after botulinum toxin A prostatic injections. *Incont Pelvic Floor Dysfunct* 2007; 1:25. (Clinical pearl)
  149. Kuo HC. Male suburethral sling for stress urinary incontinence. *Incont Pelvic Floor Dysfunct* 2007; 1:27-8. (Clinical pearl)
  150. Kuo HC. Therapeutic strategies for interstitial cystitis. *Incont Pelvic Floor Dysfunct* 2007; 1:33-6. (Review)
  151. Kuo HC. Transurethral incision of the bladder neck in treatment of chronic urinary retention after radical hysterectomy. *Incont Pelvic Floor Dysfunct* 2007; 1:49-50. (Case analysis)
  152. Kuo HC. Interpretation of uroflowmetry. *Incont Pelvic Floor Dysfunct* 2007; 1:51-5. (Clinical pearl)
  153. Kuo HC. Spinal cord injury with detrusor sphincter dyssynergia. *Incont Pelvic Floor Dysfunct* 2007; 1:57. (Clinical pearl)
  154. Kuo HC. Dysfunctional voiding and urgency frequency syndrome. *Incont Pelvic Floor Dysfunct* 2007; 1:58. (Clinical pearl)
  155. Kuo HC. Intrinsic sphincter deficiency after radical prostatectomy. *Incont Pelvic Floor Dysfunct* 2007; 1:59. (Clinical pearl)
  156. Kuo HC. Sling penetration into the bladder after anti-incontinence surgery. *Incont Pelvic Floor Dysfunct* 2007; 1:63. (Clinical pearl)
  157. Kuo HC. Videourodynamic analysis of pathophysiology of men with both storage and voiding lower urinary tract symptoms. *Urology* 2007; 70:272-6.
  158. Kuo HC. Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin A for idiopathic detrusor overactivity. *J Urol* 2007; 178:1359-63.
  159. Liao YM, Kuo HC. Causes of failed urethral botulinum toxin A treatment for emptying failure. *Urology* 2007; 70:763-6. (Correspondence)
  160. Kuo HC. Comparison of the therapeutic effects of urethral injections of 50 and 100 units of botulinum A toxin for voiding dysfunction. *Tzu Chi Med J* 2007; 19:134-8.
  161. Liu HT, Kuo HC. Increased expression of transient receptor potential vanilloid subfamily 1 in the bladder predicts the response to intravesical instillations of resiniferatoxin in patients with refractory idiopathic detrusor overactivity. *BJU Int* 2007; 100:1086-90. (Correspondence)
  162. Chiu B, Kuo HC. Therapeutic effectiveness of dutasteride in clinical benign prostatic hyperplasia in Taiwanese men. *Incont Pelvic Floor Dysfunct* 2007; 1:95-7. (Correspondence)
  163. Chuang FC, Kuo HC. Urological complications of radical hysterectomy for uterine cervical cancer. *Incont Pelvic Floor Dysfunct* 2007; 1:77-80. (Correspondence) (Review)
  164. Kuo HC. Urinary incontinence in a woman. *Incont Pelvic Floor Dysfunct* 2007; 1:101.

(Clinical pearl)

165. Kuo HC. Bladder outlet obstruction after endoscopic bladder neck suspension for stress urinary incontinence. *Incont Pelvic Floor Dysfunct* 2007; 1:102. (Clinical pearl)
166. Kuo HC. Chronic spinal cord injury with detrusor sphincter dyssynergia (DSD) type 2. *Incont Pelvic Floor Dysfunct* 2007; 1:103. (Clinical pearl)
167. Kuo HC. Postprostatectomy urgency and urge incontinence. *Incont Pelvic Floor Dysfunct* 2007; 1:105. (Clinical pearl)
168. Kuo HC. Urethral fibrosis as an etiology of female bladder outlet obstruction. *Incont Pelvic Floor Dysfunct* 2007; 1:107. (Clinical pearl)
169. Kuo HC. Pubovaginal sling procedure using a polypropylene mesh sling for stress urinary incontinence. *Incont Pelvic Floor Dysfunct* 2007; 1:111-3. (Clinical pearl)
170. Kuo HC. Dutasteride treatment for symptomatic benign prostatic hyperplasia in Taiwan. *Incont Pelvic Floor Dysfunct* 2007; 1(Suppl 2):25-9. (Review)
171. Liao YM, Kuo HC. Recent advances in the treatment of overactive bladder. *JTUA* 2007; 18:6169. (Correspondence) (Review)
172. Wang SN, Kuo HC. Videourodynamic findings in Parkinson's disease. *JUTA* 2007; 18:23-6. (Correspondence)
173. Chen YC, Liao YM, Kuo HC. Lower urinary tract dysfunction in stroke patients. *JUTA* 2007; 18:147-50. (Correspondence)
174. Liu HT, Kuo HC. Intravesical botulinum toxin A injections plus hydrodistension can reduce nerve growth factor production and control bladder pain in interstitial cystitis. *Urology* 2007; 70: 463-8. (Correspondence)
175. Chen CY, Liao YM, Tsai WM, Kuo HC. Upper urinary tract urothelial carcinoma in eastern Taiwan: High proportion among all urothelial carcinomas and correlation with chronic kidney disease. *J Formos Med Assoc* 2007; 106:992-8. (Correspondence)
176. Kuo HC. Botulium A toxin treatment for voiding dysfunction. *Incont Pelvic Floor Dysfunct* 2007; 1:117-9. (Review)
177. Kuo HC. Physical examination and office-based assessment of women with urinary incontinence and pelvic organ prolapse. *Incont Pelvic Floor Dysfunct* 2007; 1:131-6. (Correspondence) (Review)
178. Kuo HC. Hesitancy and small caliber of urine refractory to alpha-blocker therapy. *Incont Pelvic Floor Dysfunct* 2007; 1:145. (Clinical pearl)
179. Kuo HC. Lower abdominal discomfort and urinary incontinence in a woman. *Incont Pelvic Floor Dysfunct* 2007; 1:146. (Clinical pearl)
180. Kuo HC. Severe dysuria and miction pain in a young man. *Incont Pelvic Floor Dysfunct* 2007; 1:147. (Clinical pearl)
181. Kuo HC. Editorial comment on: urinary incontinence at orgasm: relation to detrusor overactivity and treatment efficacy. *Eur Urol* 2008; 54:915-6. (Comment)
182. Liu HT, Kuo HC. Urinary nerve growth factor level could be a potential biomarker for diagnosis of overactive bladder. *J Urol* 2008; 179:2270-4. (Correspondence)

183. Kuo HC. Treatment strategies for neurogenic voiding dysfunction. *Tzu Chi Med J* 2008; 20:35-9. (Review)
184. Kuo HC. Guidelines for diagnostic assessment and advanced study of lower urinary tract symptoms suggestive of benign prostatic hyperplasia. *Incont Pelvic Floor Dysfunct* 2008; 2:7-10. (Review)
185. Kuo HC. Novel treatment of overactive bladder and detrusor overactivity with intravesical resiniferatoxin. *Incont Pelvic Floor Dysfunct* 2008; 2:17-20. (Review)
186. Kuo HC. Dysuria and urgency frequency in a patient with Parkinson's disease. *Incont Pelvic Floor Dysfunct* 2008; 2:21. (Clinical pearl)
187. Kuo HC. Possible Fowler's syndrome and chronic urinary retention. *Incont Pelvic Floor Dysfunct* 2008; 2:23. (Clinical pearl)
188. Liu HT, Kuo HC. Urinary nerve growth factor level is a potential biomarker of overactive bladder and detrusor overactivity. *Incont Pelvic Floor Dysfunct* 2008; 2:27-9. (Clinical pearl)
189. Kuo HC. Voiding in a man with bladder diverticulum. *Incont Pelvic Floor Dysfunct* 2008; 2:36-7. (Clinical pearl)
190. Kuo HC. Technical points of botulinum toxin A injections in the treatment of lower urinary tract dysfunction. *Incont Pelvic Floor Dysfunct* 2008; 2:41-4. (Review)
191. Kuo HC. Dysfunctional voiding in a woman. *Incont Pelvic Floor Dysfunct* 2008; 2:85. (Clinical pearl)
192. Ke QS, Kuo HC. Combination therapy using an  $\alpha$ -blocker together with an antimuscarinic agent for treatment of men with benign prostatic obstruction and overactive bladder: results of clinical experience and a mini-review. *Incont Pelvic Floor Dysfunct* 2008; 2(Suppl 1):21-4. (Correspondence) (Review)
193. Lim EK, Kuo HC. The treatment of overactive bladder syndrome refractory to antimuscarinic therapy. *Incont Pelvic Floor Dysfunct* 2008; 2(Suppl 1):29-32. (Review)
194. Kuo HC. The role of urodynamic study in the evaluation and management of overactive bladder. *Incont Pelvic Floor Dysfunct* 2008; 2:95-7. (Review)
195. Kuo HC. Botulinum toxin A injections for overactive bladder. *Incont Pelvic Floor Dysfunct* 2008; 2:107-11. (Review)
196. Kuo HC. Cauda equine lesion with urinary incontinence and difficult urination. *Incont Pelvic Floor Dysfunct* 2008; 2:113. (Clinical pearl)
197. Kuo HC. Idiopathic detrusor overactivity without bladder outlet obstruction in a 77 year-old man. *Incont Pelvic Floor Dysfunct* 2008; 2:115. (Clinical pearl)
198. Kuo HC. Detrusor underactivity with a contracted bladder and bilateral vesicoureteral reflux. *Incont Pelvic Floor Dysfunct* 2008; 2:117-18. (Clinical pearl)
199. Kuo HC. Parkinson's disease and urge urinary incontinence. *Incont Pelvic Floor Dysfunct* 2008; 2:119. (Clinical pearl)
200. Liu HT, Kuo HC. Urinary nerve growth factor levels are increased in patients with bladder outlet obstruction with overactive bladder symptoms and reduced after successful medical treatment. *Urology* 2008; 72:104-8. (Correspondence)

201. Liu HT, Chancellor MB, Kuo HC. Urinary nerve growth factor level could be a biomarker in the differential diagnosis of mixed urinary incontinence in women. *BJU Int* 2008; 102:1440-4. (Correspondence)
202. Kuo HC. Satisfaction with urethral injection of botulinum toxin A for detrusor sphincter dyssynergia in patients with spinal cord lesion. *Neurourol Urodyn* 2008; 27:793-6.
203. Kuo HC. Prevalence of lower urinary tract symptoms in male aborigines and non-aborigines in eastern Taiwan. *J Formos Med Assoc* 2008; 107:728-35.
204. Kuo HC. Therapeutic satisfaction and dissatisfaction in patients with spinal cord lesions and detrusor sphincter dyssynergia who received detrusor botulinum toxin a injection. *Urology* 2008; 72:1056-60.
205. Kuo HC, Chuang YC, Chancellor MB. Neurourology, diet, and painful bladder: highlights of the 37th annual conference of the international continence society, august 20-24, 2007, Rotterdam, Netherlands. *Rev Urol* 2008; 10:70-2. (Review)
206. Niu Y, Yeh S, Miyamoto H, Li G, Altuwajri S, Yuan J, Han R, Ma T, Kuo HC, Chang C. Tissue prostate-specific antigen facilitates refractory prostate tumor progression via enhancing ARA70-regulated androgen receptor transactivation. *Cancer Res* 2008; 68:7110-9.
207. Chen CY, Kuo HC. Antimuscarinics can decrease urgency severity without affecting uroflow or voiding efficiency in patients with an overactive bladder. *JTUA* 2008; 19: 160-4. (Correspondence)
208. Kuo HC. Interstitial cystitis – cystoscopy, hydrodistention, potassium test, urodynamics, pathology - what is the value of each? *Incont Pelvic Floor Dysfunct* 2008; 2:129-3. (Review)
209. Kuo HC. Spastic urethral sphincter of unknown cause in a woman. *Incont Pelvic Floor Dysfunct* 2008; 2:159. (Clinical pearl)
210. Kuo HC. Urgency incontinence in an elderly man with a chronic stroke. *Incont Pelvic Floor Dysfunct* 2008; 2:161. (Clinical pearl)
211. Kuo HC. Contracted bladder after enterocystoplasty and hydronephrosis. *Incont Pelvic Floor Dysfunct* 2008; 2:162-3. (Clinical pearl)
212. Kuo HC. Difficult urination after a pubovaginal sling procedure. *Incont Pelvic Floor Dysfunct* 2008; 2:164. (Clinical pearl)
213. Liu HT, Kuo HC. Urinary nerve growth factor levels are elevated in patients with overactive bladder and do not significantly increase with bladder distention. *Neurourol Urodyn* 2009; 28:78-81. (Correspondence)
214. Liu HT, Chancellor MB, Kuo HC. Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection. *Eur Urol* 2009; 56:700-7. (Correspondence)
215. Kuo HC, Chen YC, Chen CY, Chancellor MB. Transabdominal ultrasound measurement of detrusor wall thickness in patients with overactive bladder. *Tzu Chi Med J* 2009; 21:129-35.
216. Liu HT, Liu AB, Chancellor MB, Kuo HC. Urinary nerve growth factor level is correlated with the severity of neurological impairment in patients with cerebrovascular accident. *BJU Int* 2009; 104:1158-62. (Correspondence)

217. Kuo HC, Chancellor MB. Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis/painful bladder syndrome. *BJU Int* 2009; 104:657-61.
218. Kuo HC. Overactive bladder is a dynamic syndrome. *Eur Urol* 2009; 55:792-3. (Editorial)
219. Liu HT, Chancellor MB, Kuo HC. Decrease of urinary nerve growth factor levels after antimuscarinic therapy in patients with overactive bladder. *BJU Int* 2009; 103:1668-72. (Correspondence)
220. Hsieh JH, Kuo HC. Pathophysiology of urothelial dysfunction in patients with interstitial cystitis/painful bladder pain syndrome - increased apoptosis and decreased junctional protein expression in the urothelium due to suburothelial inflammation. *Tzu Chi Med J* 2009; 21:103-9. (Correspondence) (Review)
221. Kuo HC, Liu HT. Therapeutic effects of add-on botulinum toxin A on patients with large benign prostatic hyperplasia and unsatisfactory response to combined medical therapy. *Scand J Urol Nephrol* 2009; 43:206-11.
222. Kuo HC. Detrusor overactivity in a male patient with lower urinary tract symptoms and cerebrovascular accident. *Incont Pelvic Floor Dysfunct* 2009; 3:21. (Clinical pearl)
223. Kuo HC. Parkinson's disease with overactive bladder. *Incont Pelvic Floor Dysfunct* 2009; 3:17. (Clinical pearl)
224. Kuo HC. Benign prostatic hyperplasia with bladder outlet obstruction. *Incont Pelvic Floor Dysfunct* 2009; 3:18. (Clinical pearl)
225. Kuo HC. Surgical therapies for chronic interstitial cystitis. *Incont Pelvic Floor Dysfunct* 2009; 3:7-8. (Review)
226. Chung SD, Chiu B, Chuang YC, Kuo HC. Re: Claus G. Roehrborn, Steven A. Kaplan, J. Stephen Jones, Joseph T. Wang, Tamara Bavendam, Zhonghong Guan. Tolterodine Extended Release With or Without Tamsulosin in Men With Lower Urinary Tract Symptoms Including Overactive Bladder Symptoms: Effects of Prostate Size. *Eur Urol* 2009; 55:472-81. *Eur Urol* 2009; 55:e30-1. (Correspondence) (Letter)
227. Kuo HC. Recent advances in intravesical treatment of overactive bladder. *Low Urin Tract Symptoms* 2009; 1: 2-9. (Review)
228. Kuo HC, Liu HT, Eric Guan, Chancellor MB. Novel biomarkers for diagnosis and therapeutic assessment of overactive bladder: Urinary nerve growth factor and detrusor wall thickness. *Low Urin Tract Symptoms* 2009; 1(Suppl 1):S59-S61. (Review)
229. Chen JL, Chen CY, Kuo HC. Botulinum toxin A injection to bladder neck and urethra for medically refractory lower urinary tract symptoms in men without prostatic obstruction. *J Formosa Med Assoc* 2009; 108:950-6. (Correspondence)
230. Chuang FC, Kuo HC. Videourodynamic evaluation of urge syndrome following pubovaginal sling procedure for stress urinary incontinence in women. *Int Urogynecol J* 2009; 20:1253-8. (Correspondence)
231. Ke QS, Kuo HC. A Suburethral sling for stress urinary incontinence in men. *JTUA* 2009; 20:15-20. (Correspondence)

232. Chen YC, Li MH, Kuo HC. Metastatic adrenal cortical carcinoma to the bilateral kidneys after a primary adrenalectomy 10 years previous: a case report. *JTUA* 2009; 20:34-8. (Correspondence)
233. Kuo HC. Measurement of detrusor wall thickness in women with overactive bladder by transvaginal and transabdominal sonography. *Int Urogynecol J Pelvic Floor Dysfunct* 2009; 20:1293-9.
234. Liu HT, Tyagi P, Chancellor MB, Kuo HC. Urinary nerve growth factor level is increased in patients with interstitial cystitis/bladder pain syndrome and decreased in responders to treatment. *BJU Int* 2009; 104:1476-81. (Correspondence)
235. Chen JL, Kuo HC. Long-term outcomes of augmentation enterocystoplasty with an ileal segment in patients with spinal cord injury. *J Formos Med Assoc* 2009; 108:475-80. (Correspondence)
236. Jang MY, Kuo HC. Intravesical treatment for interstitial cystitis. *Incont Pelvic Floor Dysfunct* 2009; 3: 33-5. (Review) (Correspondence)
237. Kuo HC. Detrusor underactivity without bladder outlet obstruction. *Incont Pelvic Floor Dysfunct* 2009; 3:55. (Clinical pearl)
238. Kuo HC. Spastic urethral sphincter and chronic urinary retention in a girl. *Incont Pelvic Floor Dysfunct* 2009; 3:57. (Clinical pearl)
239. Chen CY, Kuo HC. Pudendal nerve injury induced intrinsic sphincter deficiency and urinary incontinence. *Incont Pelvic Floor Dysfunct* 2009; 3:58-9. (Clinical pearl)
240. Chen CY, Kuo HC. Novel urinary biomarkers in the diagnosis and assessment of overactive bladder. *Incont Pelvic Floor Dysfunct* 2009; 3(Suppl 1):20-3. (Review) (Correspondence)
241. Homma Y, Ueda T, Tomoe H, Lin AT, Kuo HC, Lee MH, Lee JG, Kim DY, Lee KS. Interstitial cystitis guideline committee: clinical guideline for interstitial cystitis and hypersensitive bladder syndrome. *Int J Urol* 2009; 16:597-615.
242. Chuang FC, Kuo HC. Management of lower urinary tract dysfunction after radical hysterectomy with or without radiotherapy for uterine cervical cancer. *J Formos Med Assoc* 2009; 108:619-26.
243. Kuo HC. Lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a diabetic elderly man. *Incont Pelvic Floor Dysfunct* 2009; 3:81. (Clinical pearl)
244. Kuo HC. Spinal cord injury with urinary incontinence. *Incont Pelvic Floor Dysfunct* 2009; 3:82. (Clinical pearl)
245. Kuo HC. Repeated intravesical botulinum toxin A injections plus hydrodistention might be a rational treatment of interstitial cystitis refractory to conventional treatment—A hypothesis. *Incont Pelvic Floor Dysfunct* 2009; 3:91-3. (Clinical pearl)
246. Chuang YC, Kuo HC, Chancellor MB. Bladder botulinum toxin. *Low Urin Tract Symptoms* 2009; 1(Suppl 1):S22-5.
247. Kuo HC. Recent investigations of urinary nerve growth factor as a biomarker for overactive bladder syndrome. *Korean J Urol* 2009; 50:831-5.
248. Kuo HC. Intravesical botulinum toxin injection for overactive bladder-what we can learn from

previous clinical trials. *Tzu Chi Med J* 2009; 21:277-84.

249. Kuo HC. Measurement of detrusor wall thickness in women with overactive bladder by transvaginal and transabdominal sonography: reply to comment by Schaefer. *Int Urogynecol J Pelvic Floor Dysfunct* 2010; 21:131-2.
250. Chung SD, Chiu B, Kuo HC, Chuang YC, Wang CC, Guan Z, Chancellor MB. Transabdominal ultrasonography of detrusor wall thickness in women with overactive bladder. *BJU Int* 2010; 105:668-72. (Correspondence)
251. Chuang FC, Kuo HC. Prevalence of lower urinary tract symptoms in indigenous and non-indigenous women in eastern Taiwan. *J Formos Med Assoc* 2010; 109:228-36. (Correspondence)
252. Chuang YC, Kuo HC, Chancellor MB. Botulinum toxin for the lower urinary tract. *BJU Int* 2010; 105:1046-58. (Review)
253. Kuo HC. Intravesical treatment for overactive bladder refractory to antimuscarinics. *Incont Pelvic Floor Dysfunct* 2010; 4:5-9. (Review)
254. Kuo HC. Suspicious Fowler's syndrome and chronic urinary retention in a young girl. *Incont Pelvic Floor Dysfunct* 2010; 4:20. (Clinical Pearl)
255. Kuo HC. T1 spinal cord injury with difficult urination. *Incont Pelvic Floor Dysfunct* 2010; 4:21. (Clinical pearl)
256. Kuo HC. Frequency urgency and bladder pain in a woman. *Incont Pelvic Floor Dysfunct* 2010; 4:22. (Clinical pearl)
257. Kuo HC, Liu HT, Tyagi P, Chancellor MB. Urinary nerve growth factor levels in urinary tract diseases with or without frequency urgency symptoms. *Low Urin Tract Symptoms* 2010; 2:88-94.
258. Chen YC, Chen CY, Kuo HC. Efficacy and adverse effects of solifenacin in the treatment of lower urinary tract symptoms in patients with overactive bladder. *Urol Sci* 2010; 21:38-43. (Correspondence)
259. Kao SL, Hsu YH, Kuo HC. Renal oncocytoma with specific imaging findings. *Tzu Chi Med J* 2010; 22:36-8. (Case report) (Correspondence)
260. Kuo HC. Male lower urinary tract symptoms—An old problem from a new perspective. *Incont Pelvic Floor Dysfunct* 2010; 4:33-38. (Review)
261. Liao CH, Kuo HC. Measurement of international prostate symptom score subscores in male lower urinary tract symptoms. *Incont Pelvic Floor Dysfunct* 2010; 4:39-43. (Review) (Correspondence)
262. Kuo HC, Liu HT, Chancellor MB. Urinary nerve growth factor is a better biomarker than detrusor wall thickness for the assessment of overactive bladder with incontinence. *Neurourol Urodyn* 2010; 29:482-7.
263. Ke QS, Kuo HC. Transurethral incision of the bladder neck to treat bladder neck dysfunction and voiding dysfunction in patients with high-level spinal cord injuries. *Neurourol Urodyn* 2010; 29:748-52. (Correspondence)
264. Ke QS, Kuo HC. Strong correlation between the overactive bladder symptom score and

- urgency severity score in assessment of patients with overactive bladder syndrome. *Tzu Chi Med J* 2010; 22:82-6. (Correspondence)
265. Chen YC, Kuo HC. Malakoplakia of ipsilateral kidney, ureter and bladder. *Tzu Chi Med J* 2010; 22:103-5. (Correspondence)
266. Chen YC, Kuo HC. Safety and efficacy of addition of an alpha-blocker to anti-muscarinic treatment in patients with overactive bladder. *Incont Pelvic Floor Dysfunct* 2010; 4:65-8. (Review) (Correspondence)
267. Kuo HC. The application of alpha-adrenergic receptor blocker in lower urinary tract dysfunction that is beyond benign prostatic hyperplasia. *Incont Pelvic Floor Dysfunct* 2010; 4:73-8. (Review)
268. Kuo HC. Post Prostatectomy urgency incontinence in an elderly man. *Incont Pelvic Floor Dysfunct* 2010; 4:83-4. (Clinical pearl)
269. Kuo HC. Urgency and urge incontinence after intraprostatic injection of botulinum toxin A for benign prostatic hyperplasia. *Incont Pelvic Floor Dysfunct* 2010; 4:85. (Clinical pearl)
270. Kuo HC, Liu HT, Chancellor MB. Can urinary nerve growth factor be a biomarker for overactive bladder? *Rev Urol* 2010; 12:e69-e77.
271. Liu HT, Tyagi P, Chancellor MB, Kuo HC. Urinary nerve growth factor but not prostaglandin E2 increases in patients with interstitial cystitis/bladder pain syndrome and detrusor overactivity. *BJU Int* 2010; 106:1681-5. (Correspondence)
272. Liu HT, Chen YC, Kuo HC. Urinary nerve growth factor levels in overactive bladder syndrome and lower urinary tract disorders. *J Formos Med Assoc* 2010; 109:862-78. (Correspondence) (Review)
273. Kuo HC, Liao CH, Chung SD. Adverse events of intravesical botulinum toxin A injections for idiopathic detrusor overactivity: risk factors and influence on treatment outcome. *Eur Urol* 2010; 58:919-26.
274. Kuo HC. Interpretation of voiding diary in patients with lower urinary tract symptoms. *Incont Pelvic Floor Dysfunct* 2010; 4:105-10. (Review)
275. Kuo HC. Spinal cord injury with detrusor sphincter dyssynergia and difficult urination. *Incont Pelvic Floor Dysfunct* 2010; 4:113. (Clinical pearl)
276. Kuo HC. Urgency frequency after medical therapy for benign prostatic hyperplasia. *Incont Pelvic Floor Dysfunct* 2010; 4:114. (Clinical pearl)
277. Kuo HC. Dysfunctional voiding and bladder neck dysfunction. *Incont Pelvic Floor Dysfunct* 2010; 4:115. (Clinical pearl)
278. Kuo HC. Female urethral stricture and overactive bladder. *Incont Pelvic Floor Dysfunct* 2010; 4:116. (Clinical pearl)
279. Chou Eric CL, Chuang YC, Wang Eric CC, Kuo HC. Validity of the traditional Chinese version of the King's health questionnaire for Taiwanese patients with an overactive bladder. *Urol Sci* 2010; 21:180-4. (Correspondence)
280. Liu HT, Wang YS, Kuo HC. Nerve growth factor levels are increased in urine but not urothelium in patients with detrusor overactivity. *Tzu Chi Med J* 2010; 22:165-70.

(Correspondence)

## 2011~2015

281. Liu HT, Chen CY, Kuo HC. Urinary nerve growth factor in women with overactive bladder syndrome. *BJU Int* 2011; 107:799-803. (Correspondence)
282. Chung SD, Chang HC, Chiu B, Liao CH, Kuo HC. The efficacy of additive tolterodine extended release for 1-year in older men with storage symptoms and clinical benign prostatic hyperplasia. *Neurourol Urodyn* 2011; 30:568-71. (Correspondence)
283. Shie JH, Kuo HC. Higher level of cell apoptosis and abnormal E-cadherin expression in the urothelium are associated with inflammation in patients with interstitial cystitis/painful bladder syndrome. *BJU Int* 2011; 108:E136-41 (Correspondence)
284. Chen CY, Liao CH, Kuo HC. Therapeutic effects of detrusor botulinum toxin A injection on neurogenic detrusor overactivity in patients with different levels of spinal cord injury types of detrusor sphincter dyssynergia. *Spinal Cord* 2011; 49:659-64. (Correspondence)
285. Kuo HC, Liu HT, Guan Z, Tyagi P, Chancellor MB. Promise of urinary nerve growth factor for assessment of overactive bladder syndrome. *Low Urin Tract Symptoms* 2011; 3:2-9 (Review)
286. Kuo HC. Bladder base/trigone injection is safe and as effective as bladder body injection of onabotulinumtoxinA for idiopathic detrusor overactivity refractory to antimuscarinics. *Neurourol Urodyn* 2011; 30:1242-8.
287. Chung SD, Liao CH, Chen YC, Kuo HC. Urgency severity scale could predict urodynamic detrusor overactivity in patients with overactive bladder syndrome. *Neurourol Urodyn* 2011; 30:1300-4. (Correspondence)
288. Chung SD, Liu HT, Lin H, Kuo HC. Elevation of serum C-reactive protein in patients with OAB and IC/PBS implies chronic inflammation in the urinary bladder. *Neurourol Urodyn* 2011; 30:417-20. (Correspondence)
289. Liao CH, Chung SD, Kuo HC. Diagnostic value of international prostate symptom score voiding-to-storage subscore ratio in male lower urinary tract symptoms. *Int J Clin Pract* 2011; 65:552-8 (Correspondence)
290. Kuo HC. Bladder neck dysfunction in spinal cord injury. *Curr Bladder Dysfunct Rep* 2011; 6:100-9.
291. Liu HT, Lin H, Kuo HC. Increased serum nerve growth factor levels in patients with overactive bladder syndrome refractory to antimuscarinic therapy. *Neurourol Urodyn* 2011; 30:1525-9. (Correspondence)
292. Kuo HC. Reduction of urgency severity is associated with long-term therapeutic effect after intravesical onabotulinumtoxinA injection for idiopathic detrusor overactivity. *Neurourol Urodyn* 2011; 30:1497-502.
293. Chen JL, Kuo HC. A cyclooxygenase-2 inhibitor reduces serum prostatic-specific antigen levels in men with benign prostatic hyperplasia and lower urinary tract symptoms and helps

- differentiate chronic inflammation from prostate cancer. *Tzu Chi Med J* 2011; 23:32-3. (Correspondence) (Hypothesis)
294. Ke QS, Kuo HC. The promise of bladder wall thickness as a useful biomarker for objective diagnosis of lower urinary tract dysfunction. *Tzu Chi Med J* 2011; 23:1-8. (Correspondence) (Review)
295. Kuo HC, Liu SH. Effect of repeated detrusor onabotulinumtoxinA injection on bladder and renal function in patients with chronic spinal cord injuries. *Neurourol Urodyn* 2011; 30:1541-5.
296. Kuo HC. Urethral diverticulum as the etiology of urgency urinary incontinence. *Incont Pelvic Floor Dysfunct* 2011; 5:21-2. (Clinical pearl)
297. Kuo HC. Bladder diverticulum in a man with bladder neck dysfunction. *Incont Pelvic Floor Dysfunct* 2011; 5:20. (Clinical pearl)
298. Hung MJ, Chou Eric CL, Yen TW, Chuang YC, Meng E, Huang ST, Kuo HC. The development and validation of Chinese Overactive Bladder Symptom Score (OABSS). *Incont Pelvic Floor Dysfunct* 2011; 5:17-18. (Clinical pearl)
299. Liao CH, Chung SD, Kuo HC. Serum C-reactive protein levels are associated with residual urgency symptoms in patients with benign prostatic hyperplasia after medical treatment. *Urology* 2011; 78:1373-8. (Correspondence)
300. Liao CH, Chung SD, Kuo HC. Reply from Authors re: Liao CH, Chung SD, Kuo HC. Serum C-reactive protein levels are associated with residual urgency symptoms in patients with benign prostatic hyperplasia after medical treatment. *Urology* 2011; 78:1373-1379. *Urology* 2011; 78:1379. (Correspondence)
301. Jiang YH, Ke QS, Kuo HC. Clinical symptoms and videourodynamic findings of detrusor overactivity in women. *Urol Sci* 2011; 22:116-9. (Correspondence)
302. Kuo HC. Mixed intrinsic sphincter deficiency and detrusor overactivity in a woman. *Incont Pelvic Floor Dysfunct* 2011; 5:57. (Clinical pearl)
303. Kuo HC. Detrusor overactivity with poor relaxation of the pelvic floor muscles. *Incont Pelvic Floor Dysfunct* 2011; 5:58. (Clinical pearl)
304. Kuo HC. Urinary incontinence and dysuria in a patient with a spinal cord lesion. *Incont Pelvic Floor Dysfunct* 2011; 5:59. (Clinical pearl)
305. Kuo YC, Kuo HC. Clinical application of botulinum toxin A for interstitial cystitis/painful bladder syndrome. *Incont Pelvic Floor Dysfunct* 2011; 5:95-9. (Correspondence) (Review)
306. Chen YC, Kuo HC. Clinical application of botulinum toxin A in overactive bladder syndrome/detrusor overactivity. *Incont Pelvic Floor Dysfunct* 2011; 5:101-6. (Correspondence) (Review)
307. Kuo HC. Guarding reflex mimicking bladder outlet obstruction in a man. *Incont Pelvic Floor Dysfunct* 2011; 5:115. (Clinical pearl)
308. Kuo YC, Kuo HC. Potential factors that can be used to differentiate between interstitial cystitis/painful bladder syndrome and bladder oversensitivity in women. *Int J Clin Pract* 2012; 66:146-51 (Correspondence)
309. Liao CH, V.C. Lin, Chung SD, Kuo HC. Therapeutic effect of  $\alpha$ -blockers and antimuscarinics

- in male urinary tract symptoms based on the International Prostate Symptom Score ratio. *Int J Clin Pract* 2012; 66:139-45. (Correspondence)
310. Chen JL, Lee MC, Kuo HC. Reduction of cystometric bladder capacity and bladder compliance with time in patients with end-stage renal disease. *J Formos Med Assoc* 2012; 111:209-13. (Correspondence)
311. Hsiao SM, Lin HH, Kuo HC. The role of serum C-reactive protein in women with lower urinary tract symptoms. *Int Urogynecol J Pelvic Floor Dysfunct* 2012; 23:935-40. (Correspondence)
312. Shie JH, Liu HT, Kuo HC. Reply from Authors Re: Increased cell apoptosis of the urothelium is mediated by inflammation in interstitial cystitis/painful bladder syndrome. *Urology* 2012; 79:750-1(Correspondence)
313. Shie JH, Liu HT, Kuo HC. Increased cell apoptosis of the urothelium is mediated by inflammation in interstitial cystitis/painful bladder syndrome. *Urology* 2012; 79: 484.e7-e13. (Correspondence)
314. Chiu AF, Liao CH, Wang CC, Wang JH, Tsai CH, Kuo HC. High classification of chronic heart failure increases risk of overactive bladder syndrome and lower urinary tract symptoms. *Urology* 2012; 79:260-5. (Correspondence)
315. Chen YC, Kuo HC. Difficult urination does not affect the successful outcome after 100 U onabotulinumtoxinA intravesical injection in patients with idiopathic detrusor overactivity. *Low Urin Tract Symptoms* 2012; 4:29-34. (Correspondence)
316. Kuo HC. Potential biomarkers utilized to define and manage overactive bladder syndrome. *Low Urin Tract Symptoms* 2012; 4(Suppl 1):32-41.
317. Liu HT, Shie JH, Chen SH, Wang YS, Kuo HC. Differences in mast cell infiltration, E-cadherin and zonula occludens-1 expression between patients with overactive bladder and interstitial cystitis/bladder pain syndrome. *Urology* 2012; 80:225.e13-e18. (Correspondence)
318. Chung SD, Kuo YC, Kuo HC. Intravesical onabotulinumtoxinA injections for refractory painful bladder syndrome. *Pain Physician* 2012; 15:197-202 (Correspondence)
319. Kuo HC. Clinical symptoms are not reliable in the diagnosis of lower urinary tract dysfunction in women. *J Formosan Med Assoc* 2012; 111:386-91.
320. Ke QS, Chen YC, Kuo HC. Do baseline urodynamic parameters affect the treatment outcome after intravesical 100 U onabotulinumtoxinA injection in patients with idiopathic detrusor overactivity? *Tzu Chi Med J* 2012; 24:121-6. (Correspondence)
321. Yeh HL, Kuo HC, Lin ZC, Lee RP. Correlations among disease perceptions, attitudes and self-care behaviors in patients with interstitial cystitis. *Hu Li Za Zhi* 2012; 59:30-40. (Chinese)
322. Lee PR, Yeh HL, Kuo HC, Lee RP, Peng TC, Subeq YM. Relationships among clinical symptoms, bladder condition, and subjective perceptions in patients with interstitial cystitis/painful bladder syndrome. *Hu Li Za Zhi* 2012; 59:51-60. (Chinese)
323. Chiu AF, Huang MH, Wang CC, Kuo HC. Prevalence and factors associated with overactive bladder and urinary incontinence in community-dwelling Taiwanese. *Tzu Chi Med J* 2012; 24:56-60. (Correspondence)

324. Chin HY, Lin KC, Wang CJ, Chiang CH, Kuo HC. Paraurethral striated muscular structures and pelvic floor muscles contribute to resting urethral closure pressure in rats. *Int Urogynecol J Pelvic Floor Dysfunct* 2012; 23:1631-6. (Correspondence)
325. Kuo HC. Recent advances in the application of urodynamic testing in men -A review. *Incont Pelvic Floor Dysfunct* 2012; 6:1-7. (Correspondence) (Review)
326. Kuo HC. Cervical spinal cord injury with nocturnal enuresis. *Incont Pelvic Floor Dysfunct* 2012; 6:17. (Clinical pearl)
327. Kuo HC. Chronic urinary retention in a woman with diabetes. *Incont Pelvic Floor Dysfunct* 2012; 6:18. (Clinical pearl)
328. Chuang FC, Kuo HC. Videourodynamic differential diagnosis of voiding dysfunction in Taiwanese women. *Tzu Chi Med J* 2012; 24:51-5. (Correspondence)
329. Chiu AF, Huang MH, Wang CC, Kuo HC. Higher glycosylated hemoglobin level increase risk of overactive bladder syndrome in patients with type 2 diabetes mellitus. *Int J Urol* 2012; 19:995-1001. (Correspondence)
330. Huang MH, Chiu AF, Wang CC, Kuo HC. Prevalence and risk factors for nocturia in middle-aged and elderly people from public health centers in Taiwan. *Int Braz J Urol* 2012; 38:818-24. (Correspondence)
331. Wu WC, Chung SD, Kuo HC. OnabotulinumtoxinA for the treatment of interstitial cystitis refractory to conventional therapy. *Tzu Chi Med J* 2012; 24:43-5. (Review)
332. Liu HT, Kuo HC. Increased urine and serum nerve growth factor levels in interstitial cystitis suggest chronic inflammation is involved in the pathogenesis of disease. *PLoS ONE* 2012; 7:e44687. (Correspondence)
333. Kuo HC. Elevation of the bladder base indicates iatrogenic bladder outlet obstruction in a woman after anterior colporrhaphy. *Incont Pelvic Floor Dysfunct* 2012; 6:88. (Clinical pearl)
334. Kuo HC. Type 1 detrusor sphincter dyssynergia in a man with a spinal cord injury. *Incont Pelvic Floor Dysfunct* 2012; 6:90. (Clinical pearl)
335. Kuo HC. Novel treatment of interstitial cystitis/bladder pain syndrome based on pathophysiology. *Clin Invest* 2012; 2:1085-1100. (Review)
336. Shie JH, Kuo HC. Pathologic mechanism of the therapeutic effect of botulinum toxin A on interstitial cystitis and painful bladder syndrome. *Tzu Chi Med J* 2012; 24:170-7. (Review) (Correspondence)
337. Chen SF, Kuo HC. Improvement in autonomic dysreflexia after detrusor onabotulinumtoxinA injections in patients with chronic spinal cord injuries. *Tzu Chi Med J* 2012; 24:201-4. (Correspondence)
338. Shie JH, Liu HT, Kuo HC. Protein expression profiling in interstitial cystitis/painful bladder syndrome: A pilot study of proteins associated with inflammation, apoptosis and angiogenesis. *Urol Sci* 2012; 23:107-13. (Correspondence)
339. Kuei CH, Liao CH, Kuo HC. Urodynamic characteristics of lower tract dysfunction in patients with Parkinson's disease. *Urol Sci* 2012; 23:120-3. (Correspondence)
340. Chen YC, Wang CC, Kuo HC. Therapeutic effects of transurethral incision of the bladder neck

- on primary bladder neck dysfunction refractory to alpha-adrenergic blockade in men. *Formosan J Surg* 2012; 45:78-82. (Correspondence)
341. Kuo HC. Low detrusor contractility without bladder outlet obstruction in a woman with lower urinary tract symptoms. *Incont Pelvic Floor Dysfunct* 2013; 6:108. (Clinical pearl)
342. Kuo HC. Detrusor overactivity and urethral dysfunction in a man without bladder outlet obstruction. *Incont Pelvic Floor Dysfunct* 2013; 6:109. (Clinical pearl)
343. Hsiao SM, Lin HH, Kuo HC. International prostate symptom score for assessing lower urinary tract dysfunction in women. *Int Urogynecol J Pelvic Floor Dysfunct* 2013; 24:263-7. (Correspondence)
344. Shie JH, Liu HT, Wang YS, Kuo HC. Immunohistochemical evidence suggests repeated intravesical application of botulinum toxin A injections may improve treatment efficacy of interstitial cystitis/bladder pain syndrome. *BJU Int* 2013; 111:638-46. (Correspondence)
345. Jiang YH, Kuo HC, Hsu YH. Renal endometriosis mimicking an angiomyolipoma. *Urol Sci* 2013; 24:24-6. (Correspondence)
346. Peng CH, Jhang JF, Shie JH, Kuo HC. Down regulation of vascular endothelial growth factor is associated with decreased inflammation after intravesical onabotulinumtoxinA injections combined with hydrodistention for patients with interstitial cystitis - clinical results and immunohistochemistry analysis. *Urology* 2013; 82:1452.e1-6. (Correspondence)
347. Jiang YH, Wang CC, Chuang FC, Ke QS, Kuo HC. Position of a suburethral sling at the bladder neck is associated with a higher recurrence rate of stress urinary incontinence. *J Ultrasound Med* 2013; 32:239-45. (Correspondence)
348. Lai MC, Kuo YC, Kuo HC. Intravesical hyaluronic acid for interstitial cystitis/painful bladder syndrome: A comparative randomized assessment of different regimens. *Int J Urol* 2013; 20:203-7. (Correspondence)
349. Jiang YH, Peng CH, Liu HT, Kuo HC. Increased pro-inflammatory cytokines, C-reactive protein and nerve growth factor expressions in serum of patients with interstitial cystitis/bladder pain syndrome. *PLOS ONE* 2013; 8:e76779. (Correspondence)
350. Kuei CH, Liao CH, Kuo HC. Urodynamic characteristics of voiding dysfunction in patients with cerebrovascular accidents. *Urol Sci* 2013; 24:21-3. (Correspondence)
351. Kuo HC. Repeated onabotulinumtoxin-A injections provide better results than single injection in treatment of painful bladder syndrome. *Pain Physician* 2013; 16:E15-E23.
352. Liao CH, Kuo HC. Increased risk of large post-void residual urine and decreased long-term success rate after intravesical onabotulinumtoxin A injection for refractory idiopathic detrusor overactivity. *J Urol* 2013; 189:1804-10. (Correspondence)
353. Kuo HC, Liu HT, Shie JH. Potential urine and serum biomarkers for patients with overactive bladder and interstitial cystitis/bladder pain syndrome. *Tzu Chi Med J* 2013; 25:13-8. (Review)
354. Chuang FC, Huang KH, Kuo HC. Lower urinary tract symptoms and video-urodynamic characteristics of women with clinically unsuspected bladder outlet obstruction. *Low Urin Tract Symptoms* 2013; 5:23-7. (Correspondence)

355. Hung MJ, Chou CL, Yen TW, Chuang YC, Meng E, Huang ST, Kuo HC. Development and validation of the Chinese Overactive Bladder Symptom Score for assessing overactive bladder syndrome in a RESORT study. *J Formos Med Assoc* 2013; 112:276-82. (Correspondence)
356. Lee CL, Kuo HC. Intravesical botulinum toxin A injections do not benefit patients with ulcer type interstitial cystitis. *Pain Physician* 2013; 16:109-16. (Correspondence)
357. Kuo YC, Kuo HC. The urodynamic characteristic and prognostic factors of patients with interstitial cystitis/bladder pain syndrome. *Int J Clin Pract* 2013; 67:863-9. (Correspondence)
358. Liu HT, Jiang YH, Kuo HC. Increased serum adipokines implicate chronic inflammation in the pathogenesis of overactive bladder syndrome refractory to antimuscarinic therapy. *PLOS ONE* 2013; 8:e76706. (Correspondence)
359. Kuo HC. Repeated intravesical onabotulinumtoxinA injections are effective in treatment of refractory interstitial cystitis/bladder pain syndrome. *Int J Clin Pract* 2013; 67:427-34.
360. Liao CH, Kuo YC, Kuo HC. Predictors of successful first-line antimuscarinic monotherapy in men with enlarged prostate and predominant storage symptoms. *Urology* 2013; 81:1030-3. (Correspondence)
361. Wu MP, Weng SF, Hsu YW, Wang JJ, Kuo HC. Medical attendance for lower urinary tract symptoms is associated with subsequent increased risk of outpatient visits and hospitalizations based on a nationwide population-based database. *PLOS ONE* 2013; 8:e57825. (Correspondence)
362. Kuo HC. Therapeutic outcome and quality of life between urethral and detrusor botulinum toxin treatment for patients with spinal cord lesions and detrusor sphincter dyssynergia. *Int J Clin Pract* 2013; 67:1044-9.
363. Wang CC, Kuo HC. Satisfaction and quality of life issues in patients receiving urethral botulinum toxin A injections for detrusor sphincter dyssynergia and detrusor botulinum toxin A injections for neurogenic detrusor overactivity. *Tzu Chi Med J* 2013; 25:195-9. (Review)
364. Chen YC, Kuo HC. The therapeutic effects of repeated detrusor injections between 200 or 300 units of onabotulinumtoxinA in chronic spinal cord injured patients. *Neurourol Urodyn* 2013; 33:129-34. (Correspondence)
365. Jiang YH, Victor Lin CH, Liao CH, Kuo HC. International Prostatic Symptom Score - voiding/storage subscore ratio in association with total prostatic volume and maximum flow rate is diagnostic of bladder outlet-related lower urinary tract dysfunction in men with lower urinary tract symptoms. *PLOS ONE* 2013; 8:e59176. (Correspondence)
366. Kuo YC, Kuo HC. The role of urodynamic study in the evaluation of interstitial cystitis/painful bladder syndrome. *Tzu Chi Med J* 2013; 25:131-4. (Correspondence) (Review)
367. Chou YC, Jiang YH, T Harnd, Kuo HC. Characteristics of neurogenic voiding dysfunction in cerebellar stroke: a cross-sectional, retrospective video urodynamic study. *Cerebellum* 2013; 12:601-6. (Correspondence)
368. Kuo HC. Long-term care of patients with interstitial cystitis is appreciated. *Urol Sci* 2013; 24:1. (Editorial)
369. Jhang JF, Hsu YH, Kuo HC. Characteristics and electrocauterization of Hunner's lesions

- associated with bladder pain syndrome. *Urol Sci* 2013; 24:51-55. (Correspondence)
370. Kuo YC, Kuo HC. Botulinum toxin injection for lower urinary tract. *Int J Urol* 2013; 20:40-55. (Review) (Correspondence)
371. Chuang FC, Kuo HC. Increased urothelial cell apoptosis and chronic inflammation are associated with recurrent urinary tract infection in women. *PLOS ONE* 2013; 8:e63760. (Correspondence)
372. Liao CH, Chung SD, Kuo HC. First-line antimuscarinic monotherapy is safe and effective in men with predominant storage symptoms of the lower urinary tract. *Tzu Chi Med J* 2013; 25:98-102. (Correspondence)
373. Lee CL, Jiang YH, Kuo HC. Increased apoptosis and suburothelial inflammation in patients with ketamine-related cystitis: a comparison with non-ulcerative interstitial cystitis and controls. *BJU Int* 2013; 112:1156-62. (Correspondence)
374. Jhang JF, Jiang YH, Kuo HC. Adding Cyclooxygenase-2 inhibitor to alpha blocker for patients with benign prostate hyperplasia and elevated serum prostate specific antigen could not improve prostate biopsy detection rate but improve lower urinary tract symptoms. *Int J Clin Pract* 2013; 67:1327-33. (Correspondence)
375. Chiu AF, Huang MH, Chiu JF, Kuo HC. Health-related quality of life in people with overactive bladder symptoms: reliability and validity of the traditional Chinese version of the Kings' Health Questionnaire. *Int J of Urol Nurs* 2013; 7:154-60.
376. Hsiao SM, Lin HH, Kuo HC. Factors associated with a better therapeutic effect of solifenacin in patients with overactive bladder syndrome. *Neurourol Urodyn* 2014; 33:331-4. (Correspondence)
377. Hung SF, Chung SD, Kuo HC. Increased serum C-reactive protein level is associated with increased storage lower urinary tract symptoms in men with benign prostatic hyperplasia. *PLOS ONE* 2014; 9:e85588. (Correspondence)
378. Wang CC, Liao CH, Kuo HC. Diabetes mellitus does not affect the efficacy and safety of intravesical onabotulinumtoxinA injection in patients with refractory detrusor overactivity. *Neurourol Urodyn* 2014;33:1235-9. (Correspondence)
379. Kuo HC. Potential urine and serum biomarkers for patients with bladder pain syndrome/interstitial cystitis. *Int J Urol* 2014; 21(Suppl 1):34-41. (Review)
380. Huang MH, Chiu AF, Kuo HC. Reliability and validity of the King' health questionnaire for male lower urinary tract symptoms in Taiwan. *Low Urin Tract Symptoms* 2014; 6:11-4. (Correspondence)
381. Chou CL, Hung MJ, Yen TW, Chuang YC, Meng E, Huang ST, Kuo HC. The translation and validation of Chinese Overactive Bladder Symptom Score for assessing overactive bladder syndrome and response to solifenacin treatment. *J Formos Med Assoc* 2014; 113:506-12. (Correspondence)
382. Chen YC, Kuo HC. Clinical and video urodynamic characteristics of adult women with dysfunctional voiding. *J Formos Med Assoc* 2014; 113:161-5. (Correspondence)
383. Chen SF, Jiang YH, Jhang JF, Lee CL, Kuo HC. Bladder management and urological

- complications in patients with chronic spinal cord injured in Taiwan. *Tzu Chi Med J* 2014; 26:25-8. (Correspondence)
384. Victor C. Lin, Liao CH, Kuo HC. Progression of lower urinary tract symptoms after discontinuation of 1 medication from 2-year combined alpha-blocker and 5-alpha-reductase inhibitor therapy for benign prostatic hyperplasia in men – a randomized multicenter study. *Urology* 2014; 83:416-21. (Correspondence)
385. Lee MH, Lin Alex TL, Kuo HC, Chen YF. Clinical characteristic picture and impact of symptoms on quality of life of interstitial cystitis patients in Taiwan. *Low Urin Tract Symptoms* 2014; 6:20-5.
386. Jhang JF, Jiang YH, Kuo HC. Potential therapeutic effect of intravesical botulinum toxin type A on bladder pain syndrome/interstitial cystitis. *Int J Urol* 2014; 21(Suppl 1):49-55. (Review)
387. Jhang JF, Jiang YH, Kuo HC. Transurethral incision of the bladder neck improves voiding efficiency in female patients with detrusor underactivity. *Int Urogynecol J* 2014; 25:671-6. (Correspondence)
388. Jhang JF, Liao CH, Kuo HC. Severity of lower urinary tract symptoms reflects different composition of bladder storage dysfunction and bladder outlet obstruction in men with symptomatic benign prostatic hyperplasia. *Int J Clin Pract* 2014; 68:743-8. (Correspondence)
389. Chung SD, Wang CC, Kuo HC. Augmentation enterocystoplasty is effective in relieving refractory ketamine-related bladder pain. *Neurourol Urodyn* 2014; 33:1207-11. (Correspondence)
390. Lai EC, Kao Yang YH, Kuo HC. Complication rate of neurogenic lower urinary tract dysfunction after spinal cord injury in Taiwan. *Int Urol Nephrol* 2014; 46:1063-71.
391. Tyagi P, Tyagi V, Qu X, Lin HT, Kuo HC, Chuang YC, Chancellor M. Association of inflammaging (inflammation + aging) with higher prevalence of OAB in elderly population. *Int Urol Nephrol* 2014; 46:871-7.
392. Lee CL, Su BC, Kuo HC. The dreadful and the deadly erection-Malignant priapism from renal cell carcinoma. *Urol Sci* 2014; 25:152-4. (Correspondence)
393. Kuo HC, Liu HT, Chuang YC, Lori Birder, Chancellor MB. Pilot study of liposome-encapsulated onabotulinumtoxinA for patients with overactive bladder: A single-center study. *Eur Urol* 2014; 65:1117-24.
394. Peng CH, Kuo HC. The sociodemographic and clinical predictors of symptom severity in patients with refractory interstitial cystitis/bladder pain syndrome. *Tzu Chi Med J* 2014; 26:79-85. (Correspondence)
395. Jiang YH, Liu HT, Kuo HC. Decrease of urinary nerve growth factor but not brain-derived neurotrophic factor in patients with interstitial cystitis/bladder pain syndrome treated with hyaluronic acid. *PLOS ONE* 2014; 9:e91609. (Correspondence)
396. Jiang YH, Liao CH, Kuo HC. How much improvement is needed for a real difference of lower urinary tract symptoms after long-term combination therapy for benign prostatic hyperplasia. *Int J Clin Pract* 2014; 68:1081-6. (Correspondence)
397. Chuang FC, Liu HT, Wang LY, Kuo HC. Overactive bladder changes with time: A 5-year

- longitudinal follow up of changes in overactive bladder symptoms, urodynamic studies and urinary nerve growth factor levels. *J Urol* 2014; 192:458-63. (Correspondence)
398. Kuo HC, Chen SL, Chou CL, Chuang YC, Huang YH, Juan YS, Lee WC, Liao CH, Tsai YC, Tsai YA, Wang CC. Taiwanese Continence Society clinical guidelines for diagnosis and management of neurogenic lower urinary tract dysfunction. *Urol Sci* 2014; 25:35-41.
399. Kuo HC. Botulinum toxin A injections for non-neurogenic overactive bladder. *Curr Bladder Dysfunct Rep* 2014; 9:254-60. (Review)
400. Jhang JF, Hsu YH, Jiang YH, Kuo HC. Elevated serum immunoglobulin E may be associated to the development of ketamine cystitis. *J Urol* 2014; 192:1249-56. (Correspondence)
401. Liao CH, Kuo HC. Use of the International Prostate Symptom Score voiding-to-storage subscore ratio in assessing lower urinary tract symptoms. *Tzu Chi Med J* 2014; 26:61-3. (Correspondence)
402. Chuang YC, Kaufmann JH, Chancellor D, Chancellor MB, Kuo HC. Bladder instillation of Liposome encapsulated onabotulinumtoxinA improves overactive bladder symptoms: A prospective, multicenter, double-blind randomized trial. *J Urol* 2014; 192:1743-9. (Correspondence)
403. Jiang YH, Liao CH, Tang DL, Kuo HC. Efficacy and safety of intravesical onabotulinumtoxinA injection on elderly patients with chronic central nervous system lesions and overactive bladder. *PLoS ONE* 2014; 9:e105989. (Correspondence)
404. Chen JL, Chen SF, Kuo HC. Clinical assessment and management of patients with National Institutes of Health categories IIIA and IIIB chronic prostatitis/chronic pelvic pain syndrome. *Tzu Chi Med J* 2014; 26:151-6. (Correspondence) (Review)
405. Kuo HC, Chen SL, Chou CL, Chuang YC, Huang YH, Juan YS, Lee WC, Liao CH, Tsai YC, Tsai YA, Wang CC. Clinical guidelines for the diagnosis and management of neurogenic lower urinary tract dysfunction. *Tzu Chi Med J* 2014; 26:103-13. (Review)
406. Jiang YH, Kuo HC. Urothelial dysfunction and increased suburothelial inflammation of urinary bladder are involved in patients with upper urinary tract urolithiasis - Clinical and immunohistochemistry study. *PLoS ONE* 2014;9:e110754. (Correspondence)
407. Liao CH, Kuo HC. How to choose first-line treatment for men with predominant storage lower urinary tract symptoms: A prospective randomized comparative study. *Int J Clin Pract* 2015; 69:124-30. (Correspondence)
408. Victor C. Lin, Liao CH, Wang CC, Kuo HC. 5 $\alpha$ -reductase inhibitor is less effective in men with small prostate volume and low serum prostatic specific antigen level. *J Formos Med Assoc* 2015; 114:865-71. (Correspondence)
409. Chen SF, Kuo HC. Therapeutic outcome and patient adherence to repeated onabotulinumtoxinA detrusor injections in chronic spinal cord injured patients and neurogenic detrusor overactivity. *J Formosan Med Assoc* 2015; 114:583-9. (Correspondence)
410. Liu HT, Jiang YH, Kuo HC. Alteration of urothelial inflammation, apoptosis, and junction protein in patients with various bladder conditions and storage bladder symptoms suggest common pathway involved in underlying pathophysiology. *Low Urin Tract Symptoms* 2015;

7:102-7. (Correspondence)

411. Ke QS, Jiang YH, Kuo HC. Role of bladder neck and urethral sphincter dysfunction in men with persistent bothersome lower urinary tract symptoms after  $\alpha$ -1 blocker treatment. *Low Urin Tract Symptoms* 2015; 7:143-8. (Correspondence)
412. Kuo HC, Lee KS, Na Y, Sood R, Nakaji S, Kubota Y, Kuroishi K. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a  $\beta$ 3-adrenoceptor agonist, in patients with overactive bladder in Asian. *Neurourol Urodyn* 2015; 34:685-92.
413. Jiang YH, Liu HT, Kuo HC. Urothelial dysfunction and chronic inflammation in patients with spinal cord injuries at different levels and correlation with urodynamic findings. *Neurourol Urodyn* 2015; 34:757-62. (Correspondence)
414. Lee CL, Peng CH, Kuo HC. Therapeutic effects and predictive factors for successful intravesical hyaluronic acid instillation on interstitial cystitis/bladder pain syndrome. *Urol Sci* 2015; 26:125-30. (Correspondence)
415. Jhang JF, Jiang YH, Lee CL, Kuo HC. Clinical presentation and underlying pathophysiology of an underactive bladder. *Tzu Chi Med* 2015; 27:1-6 (Correspondence) (Review)
416. Tsai YC, Kuo HC. Ketamine cystitis: Its urological impact and its management. *Urol Sci* 2015; 26:153-7. (Correspondence) (Review)
417. Huang KT, Victor C. Lin, Tsai YC, Kuo HC. Predictive factors from videourodynamic study for delayed urinary continence after laparoscopic radical prostatectomy. *Urol Sci* 2015; 26:31-5. (Correspondence)
418. Wang CC, Liao CH, Kuo HC. Clinical guidelines for male lower urinary tract symptoms associated with non-neurogenic overactive bladder. *Urol Sci* 2015; 26:7-16. (Correspondence) (Review)
419. Kuo HC. Treatment of overactive bladder: Past, present, and future. *Urol Sci* 2015; 26:1-2. (Editorial)
420. Kuo HC, Lin HH, Yu HJ, Cheng CL, Hung MJ, Lin TL and Taiwan Mirabegron Study Team. Results of a randomized, double-blind, placebo-controlled, study of mirabegron in Taiwanese with overactive bladder and comparison with other clinical trials. *Urol Sci* 2015; 26:41-8.
421. Liu HT, Kuo HC. Biomarkers for patients with interstitial cystitis/bladder pain syndrome. *Urol Sci* 2015; 26:225-9. (Correspondence) (Review)
422. Liao CH, Kuo HC. Practical aspects of botulinum toxin-A treatment in patients with overactive bladder syndrome. *Int Neurourol J* 2015; 19:213-9. (Correspondence) (Review)
423. Jhang JF, Hsu YH, Kuo HC. Possible Pathophysiology of Ketamine Related Cystitis and Associated Treatment Strategies. *Int J Urol* 2015; 22:816-25. (Correspondence) (Review)
424. Jhang JF, Kuo HC. Novel treatment of chronic bladder pain syndrome and other pelvic pain disorders by onabotulinumtoxinA injection. *Toxins* 2015; 7:2232-50. (Correspondence) (Review)
425. Liu HT, Chen SH, Chancellor MC, Kuo HC. Presence of cleaved synaptosomal-associated protein-25 and decrease of purinergic receptors P2X3 in the bladder urothelium influence

- efficacy of botulinum toxin treatment for overactive bladder syndrome. PLoS ONE 2015; 10: e0134803. (Correspondence)
426. Jhang JF, Kuo HC. Role of serum immunoglobulin E in patients with interstitial cystitis/bladder pain syndrome. Urol Sci 2015; 26:202-5. (Correspondence)
427. Jiang YH, Liao CH, Kuo HC. Current and potential urological applications of botulinum toxin A. Nat Rev Urol 2015; 12:519-33. (Correspondence)
428. Kuo YC, Kuo HC. O'Leary-Sant Symptom index predicts the treatment outcome for onabotulinumtoxinA injections for refractory interstitial cystitis/bladder pain syndrome. Toxins 2015; 7:2860-71. (Correspondence)
429. Hsiao SM, Liao CH, Lin HH, Kuo HC. Duration of antimuscarinic administration for treatment of overactive bladder before which one can assess efficacy: An analysis of predictive factor. Int Neurourol J 2015; 19:171-7. (Correspondence)
430. Lee CL, Kuo HC. Long-term efficacy and safety of repeated intravesical onabotulinumtoxinA injections plus hydrodistention in the treatment of interstitial cystitis/ bladder pain syndrome. Toxins 2015; 7:4283-93. (Correspondence)
431. Ke QS, Kuo HC. Pathophysiology of interstitial cystitis/ bladder pain syndrome. Tzu Chi Med J 2015; 27:139-44. (Review) (Correspondence)
432. Cheng CH, Kuo HC, Su B. Endometriosis in a kidney with focal xanthogranulomatous pyelonephritis and a perinephric abscess. BMC Research Notes 2015; 8:591.
433. Wu HT, Jiang YH, Liu AB, Ou YN, Liu CW, Kuo HC, Sun CK. Multiscale entropy analysis of surface electromyographic signals from urethral sphincter as a prognostic indicator for surgical candidates with primary bladder neck obstruction. Entropy 2015; 17:8089-98.

## 2016~2020

434. Kuo HC. OnabotulinumtoxinA treatment for overactive bladder in the elderly: Practical points and future prospects. Drugs Aging 2016; 33:1-9. (Review)
435. Lin CD, Kuo HC, Yang SD. Diagnosis and management of bladder outlet obstruction in women. Low Urin Tract Symptoms 2016; 8:30-7. (Review)
436. Liao CH, Chen SF, Kuo HC. Different number of intravesical onabotulinumtoxinA injections for patients with refractory detrusor overactivity do not affect treatment outcome: a prospective randomized comparative study. Neurourol Urodyn 2016; 35:717-23. (Correspondence)
437. Lee CL, Kuo HC. Videourodynamic analysis in men with lower urinary tract symptoms: correlation between age and prostate size with lower urinary tract dysfunction. Urol Sci 2016; 27:21-5. (Correspondence)
438. Jhang JF, Jiang YH, Lee CL, Kuo HC. Long-term follow-up and predictive factors for successful outcome of transurethral incision of bladder neck in women with detrusor underactivity. J Formosan Med Assoc 2016; 115:807-13. (Correspondence)
439. Chen SF, Chang CH, Kuo HC. Effect of detrusor botulinum toxin a injection on urothelial dysfunction in patients with chronic spinal cord injury: A clinical and immunohistochemistry

- study before and after treatment. *Spinal Cord* 2016; 54:889-94. (Correspondence)
440. Jhang JF, Hsu YH, Jiang YH, Kuo HC. The role of immunoglobulin E in the pathogenesis of ketamine related cystitis and ulcer type interstitial cystitis: An immunohistochemical study. *Pain Physician* 2016; 19:E581-7. (Correspondence)
441. Chuang FC, Liu HT, Kuo HC. Lower levels of urinary nerve growth factor might predict recurrent urinary tract infection in women. *Int Neurourol J* 2016; 20:33-9. (Correspondence)
442. Chen JL, Chen SF, Jiang YH, Kuo HC. Practical points in the medical treatment of overactive bladder and nocturia in the elderly. *Tzu Chi Med J* 2016; 28:1-5. (Correspondence)
443. Hsiao SM, Lin HH, Kuo HC. Factors associated with therapeutic efficacy of intravesical onabotulinumtoxinA injection for overactive bladder syndrome. *PLoS ONE* 2016; 11:e0147137. (Correspondence)
444. Kuo HC, Jiang YH, Tsai YC, Kuo YC. Intravesical botulinum toxin-A injections reduce bladder pain of interstitial cystitis/bladder pain syndrome refractory to conventional treatment – a prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial. *Neurourol Urodyn* 2016; 35:609-14.
445. Ong HL, Liao CH, Kuo HC. Long-term combination therapy with  $\alpha$ -blocker and 5- $\alpha$ -reductase inhibitor in benign prostatic hyperplasia: patient's adherence and causes of withdrawal from medication. *Int Neurourol J* 2016; 20:356-362. (Correspondence)
446. Jiang YH, Lee CL, Kuo HC. Urothelial dysfunction, suburothelial inflammation, and altered sensory protein expressions in men with bladder outlet obstruction and various bladder dysfunctions: correlation with urodynamics. *J Urol* 2016; 196:831-7. (Correspondence)
447. Jiang YH, Jhang JF, Kuo HC. Revisiting the role of potassium sensitivity testing and cystoscopic hydrodistention for the diagnosis of interstitial cystitis. *PLoS ONE* 2016; 11:e0151692. (Correspondence)
448. Kuo YC, Kuo HC. Adverse events of intravesical onabotulinumtoxinA injection between patients with overactive bladder and interstitial cystitis - different mechanism of action of Botox on bladder dysfunction. *Toxins* 2016; 8:E75. (Correspondence)
449. Wang CC, Lee CL, Kuo HC. Efficacy and safety of botulinum toxin A treatment for patients with detrusor overactivity and inadequate contractility. *Toxins* 2016; 8:E82. (Correspondence)
450. Jhang JF, Kuo HC. Botulinum toxin A and lower urinary tract dysfunction: pathophysiology and mechanisms of action. *Toxins* 2016; 8:120. (Correspondence) (Review)
451. Chen SF, Chang CH, Kuo HC. Clinical efficacy and changes of urothelial dysfunction after repeated detrusor botulinum toxin A injections in chronic spinal cord-injured bladder. *Toxins* 2016; 8: E164. (Correspondence)
452. Homma Y, Ueda T, Tomoe H, Lin Alex TL, Kuo HC, Lee MH, Oh SJ, Kim JC, Lee KS. Clinical guidelines for interstitial cystitis and hypersensitive bladder updated in 2015. *Int J Urol* 2016; 23:542-9.
453. Tyagi P, Tyagi V, Ou X, Chuang YC, Kuo HC, Chancellor MB. Elevated CXC chemokines in urine non-invasively discriminate OAB from UTI. *Am J Physiol Renal* 2016; 311:F548-54.
454. Tsai YC, Lori Birder, Kuo HC. Abnormal sensory protein expression and urothelial

- dysfunction in human ketamine related cystitis. *Int Neurourol J* 2016; 20:197-202. (Correspondence)
455. Jhang JF, Hsu YH, Kuo HC. Urothelial functional protein and sensory receptors in patients with interstitial cystitis/bladder pain syndrome with and without Hunner's lesion? *Urology* 2016; 98:44-9. (Correspondence)
456. Liao CH, Kuo HC. High satisfaction with direct switching from antimuscarinics to mirabegron in patients receiving stable antimuscarinic treatment. *Medicine* 2016; 95:e4962. (Correspondence)
457. Kuo HC. Botulinum A toxin urethral sphincter injection for neurogenic or nonneurogenic voiding dysfunction. *Tzu Chi Med J* 2016; 28:89-93. (Review)
458. Jhang JF, Kuo HC. Pathomechanism of interstitial cystitis/ bladder pain syndrome and mapping the heterogeneity of disease. *Int Neurourol J* 2016; 20 (Suppl 2):S95-104. (Correspondence) (Review)
459. Jiang YH, Wang CC, Kuo HC. OnabotulinumtoxinA urethral sphincter injection as treatment for non-neurogenic voiding dysfunction – A randomized, double-blind, placebo-controlled study. *Scientific Reports* 2016; 6:38905. (Correspondence)
460. Wu SY, Jhang JF, Jiang YH, Kuo HC. Increased bladder wall thickness is associated with severe symptoms and reduced bladder capacity in patients with bladder pain syndrome. *Urol Sci* 2016; 27:263-8. (Correspondence)
461. Wang CC, Jiang YH, Kuo HC. Efficacy and adherence of flexibly adding on a second antimuscarinic agent for patients with refractory overactive bladder. *Low Urin Tract Symptoms* 2017; 9:27-32 (Correspondence)
462. Jiang YH, Kuo HC. Urothelial barrier deficits, suburothelial inflammation and altered sensory protein expressions in detrusor underactivity. *J Urol* 2017; 197:197-203. (Correspondence)
463. Jiang YH, Kuo HC. Reduction of urgency severity is the most important factor in the subjective therapeutic outcome of intravesical onabotulinumtoxinA injection for overactive bladder. *Neurourol Urodyn* 2017; 36:338-43. (Correspondence)
464. Gammie A, D'Ancona C, Kuo HC, Rosier PF. ICS teaching module: Artefacts in urodynamic pressure traces (basic module). *Neurourol Urodyn* 2017; 36:35-6. (Review)
465. Jiang YH, Ong HL, Kuo HC. Predictive factors of adverse events after intravesical suburothelial onabotulinumtoxinA injections for overactive bladder syndrome - a real-life practice of 290 cases in a single center. *Neurourol Urodyn* 2017; 36:142-7. (Correspondence)
466. Lee CL, Kuo HC. Botulinum toxin A treatment for lower urinary tract symptoms/ benign prostatic hyperplasia. *Urol Sci* 2017; 28:119-22. (Correspondence)
467. Jhang JF, Birder LA, Chancellor MB, Kuo HC. Patient characteristics for different therapeutic strategies in the management ketamine cystitis. *Neurourol Urodyn* 2017; 36:687-91. (Correspondence)
468. Chen SF, Jiang YH, Kuo HC. Urinary biomarkers in patients with detrusor underactivity with and without bladder function recovery. *Int Urol Nephrol* 2017; 49:1763-70. (Correspondence)
469. Jiang YH, Lee CL, Jhang JF, Kuo HC. Current pharmacological and surgical treatment of

- underactive bladder. *Tzu Chi Med J* 2017; 29:187-91. (Correspondence)
470. Wu SY, Jiang YH, Kuo HC. Therapeutic efficacy of a new procedure for male incontinence combining a suburethral polypropylene mesh and cardiovascular patch. *Int Neurourol J* 2017; 21:38-45. (Correspondence)
471. Jiang YH, Hong YL, Kuo HC. Urodynamic changes in patients with prostate cancer undergoing robotic-assisted radical prostatectomy: A comparison with laparoscopic radical prostatectomy. *Urol Sci* 2017; 28:174-9. (Correspondence)
472. Ong HL, Kuo HC. Urothelial dysfunction and sensory protein expressions in patients with urological or systemic diseases and hypersensitive bladder. *Urol Sci* 2017; 28:128-34. (Correspondence)
473. Liu HT, Kuo HC. Expressions of urothelial functional proteins in idiopathic detrusor overactivity patients refractory to antimuscarinic therapy with different urodynamic characteristics. *Neurourol Urodyn* 2017; 36:1313-9. (Correspondence)
474. Lee YK, Jhang JF, Kuo HC. Clinical outcome of augmentation enterocystoplasty for patients with ketamine-induced cystitis. *Pain Physician* 2017; 20:E431-6. (Correspondence)
475. Wu SY, Jiang YH, Kuo HC. Long-term outcome of augmentation enterocystoplasty in patients with end-stage bladder diseases: a single institute experience involving 102 patients. *Int Neurourol J* 2017; 21:133-8. (Correspondence)
476. Yang HH, Zhai WJ, Kuo HC. The putative involved of actin-binding proteins and cytoskeleton proteins in pathological mechanisms of ketamine cystitis - revealed by a prospective pilot study using proteomic approaches. *Proteomics Clin Appl* 2017; 11:(3-4). (Correspondence)
477. Jhang JF, Kuo HC. Bladder dysfunction in 2016: New insights into interstitial cystitis and chronic pelvic pain syndromes. *Nat Rev Urol* 2017; 14:69-70. (Correspondence)
478. Wang CC, Liao CH, Liu HT, Lin JM, Kuo HC. Association of urinary nerve growth factor levels with erectile function in young men with type 2 diabetes mellitus. *Int J Impot Res* 2017; 29:101-4. (Correspondence)
479. Lee CL, Kuo HC. Current consensus and controversy on the diagnosis of male lower urinary tract symptoms/benign prostatic hyperplasia. *Tzu Chi Med J* 2017; 29:6-11. (Correspondence) (Review)
480. Liao CH, Kuo HC. Current consensus and controversy on the treatment of male lower urinary tract symptoms/benign prostatic hyperplasia. *Tzu Chi Med J* 2017; 29:1-5. (Correspondence) (Review)
481. Hsiao SM, Lin HH, Kuo HC. Urodynamic prognostic factors for large post-void residual urine volume after intravesical injection of onabotulinumtoxinA for overactive bladder. *Sci Rep* 2017; 7:43753. (Correspondence)
482. Chuang YC, Kuo HC. A prospective, multicenter, double-blind, randomized trial of bladder instillation of liposome formulation onabotulinumtoxinA for interstitial cystitis/ bladder pain syndrome. *J Urol* 2017; 198:376-82. (Correspondence)

483. Peng CH, Chen SF, Kuo HC. Videourodynamic analysis of the urethral sphincter overactivity and the poor relaxing pelvic floor muscles in women with voiding dysfunction. *Neurourol Urodyn* 2017; 36:2169-75. (Correspondence)
484. Jiang YH, Kuo HC. Video-urodynamic characteristics of non-neurogenic, idiopathic underactive bladder in men - a comparison of men with normal tracing and bladder outlet obstruction. *PLoS ONE* 2017; 12:e0174593. (Correspondence)
485. Jiang YH, Kuo HC. Recent researches on the role of urodynamic study in the diagnosis and treatment of male lower urinary tract symptoms and urinary incontinence. *Tzu Chi Med J* 2017; 29:72-8. (Correspondence) (Review)
486. Jhang JF, Kuo HC. Recent advances in recurrent urinary tract infection from pathogenesis and biomarkers to prevention. *Tzu Chi Med J* 2017; 29:131-7. (Correspondence)
487. Kuo HC. Editorial comment on: Urinary biomarkers in women with refractory urgency urinary incontinence randomized to sacral neuromodulation versus onabotulinumtoxinA compared to controls. *J Urol* 2017; 197:1494-5. (Editorial comment)
488. Lee CL, Kuo HC. Pathophysiology of benign prostate enlargement and lower urinary tract symptoms – current concept. *Tzu Chi Med J* 2017; 29:79-83. (Correspondence) (Review)
489. Hsiao SM, Lin HH, Kuo HC. Videourodynamic studies of women with voiding dysfunction. *Sci Rep* 2017; 7:6845. (Correspondence)
490. Wang CC, Kuo HC. Urothelial dysfunction and chronic inflammation in diabetic patients with overactive bladder. *Low Urin Tract Symptoms* 2017; 9:151-6.
491. Hsiao SM, Lin HH, Kuo HC. Treatment outcome of overactive bladder patients receiving antimuscarinic therapy for more than one year. *Low Urin Tract Symptoms* 2018; 10:21-6. (Correspondence)
492. Jiang YH, Liao CH, Kuo HC. Role of bladder dysfunction in men with lower urinary tract symptoms refractory to alpha-blocker therapy: A video-urodynamic analysis. *Low Urin Tract Symptoms* 2018; 10:32-7 (Correspondence)
493. Chuang FC, Hsiao SM, Kuo HC. The Overactive Bladder Symptom Score, International Prostate Symptom Score-Storage Subscore, and Urgency Severity Score in Patients with overactive bladder and hypersensitive bladder: which scoring system is best? *Int Neurourol J* 2018; 22:99-106. (Correspondence)
494. Haque N, Masumori N, Sakamoto S, Ye Z, Yoon SJ, Kuo HC, Brotherton B, Wilson T, Mugarumath C, McLaughlin, Manyak M. Superiority of dutasteride 0.5 mg and tamsulosin 0.2 mg for the treatment of moderate to severe benign prostatic hyperplasia (BPH) in Asian men. *Int J Urol* 2018; 25:944-51.
495. Lee CL, Kuo HC. Tailoring medication for lower urinary tract symptoms in men based on International Prostate Symptom Score voiding to storage ratio. *Urology* 2018; 120:30-35. (Correspondence)
496. Wu SY, Kuo HC. A real-world experience with augmentation enterocystoplasty - high patient satisfaction with high complication rates. *Neurourol Urodyn* 2018; 37:744-50. (Correspondence)

497. Jhang JF, Kuo HC. Novel applications of onabotulinumtoxin A on lower urinary tract dysfunction. *Toxins* 2018; 10:260. (Correspondence) (Review)
498. Jiang YH, Jhang JF, Lee CL, Kuo HC. Comparative study of efficacy and safety between bladder body and trigonal intravesical onabotulinumtoxinA injection in the treatment of interstitial cystitis refractory to conventional treatment - a prospective, randomized, clinical trial. *Neurourol Urodyn* 2018; 37:1467-73. (Correspondence)
499. Jhang JF, Ho HC, Jiang YH, Lee CL, Hsu YH, Kuo HC. Electron microscopic characteristics of interstitial cystitis/bladder pain syndrome and their association with clinical condition. *PLoS ONE* 2018;13:e0198816. (Correspondence)
500. Wang HJ, Kuo HC. Long-term satisfaction and complications in women with interstitial cystitis undergoing partial cystectomy and augmentation enterocystoplasty. *Urol Sci* 2018; 29:81-5. (Correspondence)
501. Jiang YH, Wang CC, Kuo HC. Videourodynamic findings of lower urinary tract dysfunctions in men with persistent storage lower urinary tract symptoms after medical treatment. *PLoS ONE* 2018; 13:e0190704. (Correspondence)
502. Jhang JF, Hsu YH, Jiang YH, Lee CL, Kuo HC. Histopathological characteristics of ketamine-associated uropathy and their clinical association. *Neurourol Urodyn* 2018; 37:1764-72. (Correspondence)
503. Chen SF, Jiang YH, Kuo HC. Urothelial dysfunction and chronic inflammation are associated with increased bladder sensation in patients with chronic renal insufficiency. *Int Neurourol J* 2018; 22(Suppl 1):S46-54.(Correspondence)
504. Lee YK, Kuo HC. Safety and therapeutic efficacy of mirabegron 25 mg in older patients with overactive bladder and multiple comorbidities. *Geriatr Gerontol Int* 2018; 18:1330-3. (Correspondence)
505. Kuo HC. Individualizing medical treatment of overactive bladder. *Tzu Chi Med J* 2018; 30:195-9. (Review)
506. Yang TH, Chuang FC, Kuo HC. Urodynamic characteristics of detrusor underactivity in women with voiding dysfunction. *PLOS ONE* 2018; 13:e0198764. (Correspondence)
507. Liao CH, Kuo HC. Mirabegron 25 mg monotherapy is safe but less effective in male patients with overactive bladder patients and bladder outlet obstruction. *Urology* 2018; 117:115-9. (Correspondence)
508. Jhang JF, Hsu YH, Peng CW, Jiang YH, Ho HC, Kuo HC. Epstein-barr virus presence as a potential etiology of persistent bladder inflammation in human interstitial cystitis/bladder pain syndrome. *J Urol* 2018; 200:590-6. (Correspondence)
509. Jiang YH, Chen SF, Jhang JF, Kuo HC. Therapeutic effect of urethral sphincter onabotulinumtoxinA injection for urethral sphincter hyperactivity. *Neurourol Urodyn* 2018; 37:2651-7. (Correspondence)
510. Kuo YC, Kuo HC. Videourodynamic characteristics of interstitial cystitis/bladder pain syndrome - the role of bladder outlet dysfunction in the pathophysiology of interstitial cystitis. *Neurourol Urodyn* 2018; 37: 1971-7. (Correspondence)

511. Shao IH, Kuo HC. Role of poor urethral sphincter relaxation in men with voiding dysfunction refractory to alpha-blocker therapy: Clinical characteristics and predictive factors. *Low Urin Tract Symptoms* 2019; 11:8-13. (Correspondence)
512. Huang HC, Jiang YH, Lin Victor CH, Tsai YC, Kuo HC. Possible predictor of early recovery on urinary continence after laparoscopic radical prostatectomy - bladder neck level and urodynamic parameters. *J Formos Med Assoc* 2019; 118:237-43. (Correspondence)
513. Wang CC, Kuo HC. Factors associated with drug persistence of antimuscarinic agents and how to improve. *J Formos Med Assoc* 2019; 118:279-84. (Correspondence)
514. Chen SF, Jiang YH, Kuo HC. Single onabotulinumtoxinA 200 U dose improved clinical symptoms but not urothelial dysfunction in neurogenic detrusor overactivity due to spinal cord injury. *J Formos Med Assoc* 2019; 118:125-33. (Correspondence)
515. Lee KH, Kuo HC. Recovery of voiding efficiency and bladder function in male patients with non-neurogenic detrusor underactivity after transurethral bladder outlet surgery. *Urology* 2019; 123:235-41. (Correspondence)
516. Chou YC, Jiang YH, Tomor Harnod, Lee HT, Shen CC, Kuo HC. Stroke and lower urinary tract symptoms: A neurosurgical view. *Urol Sci* 2019; 30:8-13. (Correspondence) (Review)
517. Chen SF, Kuo HC. Therapeutic efficacy of low-dose (25 mg) mirabegron therapy for patients with mild to moderate overactive bladder symptoms due to central nervous system diseases. *Low Urin Tract Symptoms* 2019; 11:O53-8. (Correspondence)
518. Jiang YH, Jhang JF, Chen SF, Kuo HC. Videourodynamic factors predictive of successful onabotulinumtoxinA urethral sphincter injection for neurogenic or non-neurogenic detrusor underactivity. *Low Urin Tract Symptoms* 2019; 11:66-71. (Correspondence)
519. Chen YC, Jhang JF, Hsu YH, Kuo HC. Vascular fibrinoid necrosis in the urinary bladder of ketamine abusers-A new finding which may provide the clue to pathogenesis of ketamine-induced vesicopathy. *Low Urin Tract Symptoms* 2019; 11:O221-3. (Correspondence) (Case report)
520. Ong HL, Jiang YH, Kuo HC. Repeat retropubic suburethral sling procedure is effective for recurrent female stress urinary incontinence. *Low Urin Tract Symptoms* 2019; 11:O89-92. (Correspondence)
521. Lee CL, Kuo HC. Efficacy and safety of mirabegron, a  $\beta$ -3 adrenoceptor agonist, in patients with detrusor hyperactivity and impaired contractility. *Low Urin Tract Symptoms* 2019; 11:O93-7. (Correspondence)
522. Chen SF, Lee CL, Kuo HC. Changes in sensory proteins in the bladder urothelium of patients with chronic kidney disease and end-stage renal disease. *Low Urin Tract Symptoms* 2019; 11:O202-8. (Correspondence)
523. Wu SY, Kuo HC. Long-term outcomes of anti-incontinence surgery and subsequent transvaginal sling incision for urethral obstruction. *Int Urogynecol J* 2019; 30:761-6. (Correspondence)

524. Liao CH, Kuo HC. Mirabegron escalation to 50 mg further improves urgency and urgency urinary incontinence in Asian patients with overactive bladder. *J Formos Med Assoc* 2019; 118:700-6. (Correspondence)
525. Jhang JF, Wu SY, Lin TY, Kuo HC. Repeated intravesical injections of platelet-rich plasma is effective in treatment of interstitial cystitis - a case control pilot study. *Low Urin Tract Symptoms* 2019; 11:042-047. (Correspondence)
526. Wu SY, Jiang YH, Kuo HC. Detrusor underactivity and bladder outlet procedures in men. *Curr Bladder Dysfunct Rep* 2018; 13:274-81. (Correspondence)(Review)
527. Wang TM, Yang SD, Tsai JD, Yu MC, Chiou YH, Chen KL, Cheng HL, Lin J, Chen HW, Kuo HC, Chen SC. Management of nocturnal enuresis in Taiwan: Consensus statements of the Taiwan enuresis expert committee. *J Formosan Med Assoc* 2019; 118:965-72. (Review)
528. Jhang JF, Lin TY, Kuo HC. Intravesical injections of platelet-rich plasma is effective and safe in treatment of interstitial cystitis refractory to conventional treatment - a prospective clinical trial. *Neurourol Urodyn* 2019; 38:703-9. (Correspondence)
529. Ong HL, Kuo HC. Bladder dysfunction does not affect Long-term success rate of retropubic suburethral sling procedure in women with stress urinary incontinence. *Low Urin Tract Symptoms* 2019; 11:O168-73. (Correspondence)
530. Lee CL, Kuo HC. Male patients with higher nocturnal urinary frequency episodes are more likely to benefit from alpha-blocker therapy for bothersome nocturia. *Low Urin Tract Symptoms* 2019; 11:O174-9. (Correspondence)
531. Wang CC, Jiang YH, Kuo HC. Higher urge severity score prediction of resumption of overactive bladder (OAB) medication following discontinuation of mirabegron treatment in patients with OAB. *Low Urin Tract Symptoms* 2019; 11:O180-5. (Correspondence)
532. Rosier PFWM, Kuo HC, De Gennaro M, Gammie A, Finazzi Agro E, Kakizaki H, Hashim H, Tooze-Hobson P. International Consultation on Incontinence 2016; Executive summary: Urodynamic testing. *Neurourol Urodyn* 2019; 38:545-52. (Review)
533. Chen LC, Kuo HC. Pathophysiology of refractory overactive bladder. *Low Urin Tract Symptoms* 2019; 11:177-81. (Correspondence) (Review)
534. Jiang YH, Kuo HC. Molecular characteristics of underactive bladder. *Curr Bladder Dysfunct Rep* 2019; 14:47-57. (Correspondence) (Review)
535. Yu WR, Peng TC, Yeh HL, Kuo HC. Anxiety severity does not influence treatment outcomes in patients with interstitial cystitis / bladder pain syndrome. *Neurourol Urodyn* 2019; 38:1602-10. (Correspondence)
536. Ke QS, Jhang JF, Lin TY, Ho HC, Jiang YH, Hsu YH, Kuo HC. Therapeutic potential of intravesical injections of platelet-rich plasma in the treatment of lower urinary tract disorders due to regenerative deficiency. *Tzu Chi Med J* 2019; 31:135-43. (Correspondence) (Review)
537. Wang HJ, Yu WR, Ong HL, Kuo HC. Predictive factors for a satisfactory treatment outcome with intravesical botulinum toxin A injection in patients with interstitial cystitis/bladder pain syndrome. *Toxins* 2019; 11:E676. (Correspondence)

538. Liu HH, Kuo HC. Durability of retropubic suburethral sling procedure and predictors for successful treatment outcome in women with stress urinary incontinence. *Urology* 2019; 131:83-8. (Correspondence)
539. Yeh HL, Jhang JF, Kuo YC, Kuo HC. Long-term outcome and symptom improvement in patients with interstitial cystitis/bladder pain syndrome with or without regular follow-up and treatment. *Neurourol Urodyn* 2019; 38:1985-93. (Correspondence)
540. Lee YK, Kuo HC. Therapeutic efficacy and quality of life improvement in women with detrusor underactivity after transurethral incision of the bladder neck. *Urol Sci* 2019; 30:266-71. (Correspondence)
541. Chen SF, Lee CL, Kuo HC. Change of detrusor contractility in patients with and without bladder outlet obstruction at ten or more years of follow-up. *Sci Rep* 2019; 9:18887. (Correspondence)
542. Jhang JF, Birder L, Jiang YH, Hsu YH, Ho HC, Kuo HC. Dysregulation of bladder corticotropin-releasing hormone receptor in the pathogenesis of human interstitial cystitis/bladder pain syndrome. *Sci Rep* 2019; 9:19169. (Correspondence)
543. Chiang BJ, Kuo HC, Liao CH. Can botulinum toxin A still have a role in treatment of lower urinary tract symptoms/benign prostatic hyperplasia through inhibition of chronic prostatic inflammation? *Toxins (Basel)* 2019; 11:E547. (Review)
544. Jhang JF, Wang HJ, Hsu YH, Lori Birder, Kuo HC. Upregulation of neurotrophins and transforming growth factor- $\beta$  expression in the bladder may lead to nerve hyperplasia and fibrosis in patients with severe ketamine associated cystitis. *Neurourol Urodyn* 2019 38:2303-10. (Correspondence)
545. Lee YK, Kuo HC. Therapeutic effects of botulinum toxin A urethral sphincter injection on voiding dysfunction due to different bladder and urethral sphincter dysfunction. *Toxins* 2019; 11:E487. (Correspondence)
546. Kao YL, Huang KH, Kuo HC, YC Ou. The therapeutic effects and pathophysiology of botulinum toxin A on voiding dysfunction due to urethral sphincter dysfunction. *Toxins (Basel)* 2019; 11:728. (Review)
547. Lee PJ, Kuo HC. High incidence of lower urinary tract dysfunction in women with recurrent urinary tract infections. *Low Urin Tract Symptoms* 2020; 12:33-40. (Correspondence)
548. Wu SY, Kuo HC. Predictive factors for recovery of voiding function after transurethral prostate surgery in men with small prostate volume and very low detrusor contractility. *Low Urin Tract Symptoms* 2020; 12:41-6. (Correspondence)
549. Chen JL, Kuo HC. Clinical application of intravesical botulinum toxin type A for overactive bladder and interstitial cystitis. *Invest Clin Urol* 2020; 61(Suppl 1):S33-42.(Correspondence) (Review)
550. Lee CL, Ong HL, Kuo HC. Therapeutic efficacy of mirabegron 25 mg monotherapy in patients with nocturia-predominant hypersensitive. *Tzu Chi Med J* 2020; 32:30-5. (Correspondence)
551. Chen JL, Jiang YH, Lee CL, Kuo HC. Precision medicine in the diagnosis and treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia. *Tzu Chi Med J*

- 2020; 32:5-13. (Correspondence) (Review)
552. Jiang YH, Chen SF, Kuo HC. Role of videourodynamic study in precision diagnosis and treatment for lower urinary tract dysfunction. *Tzu Chi Med J* 2020; 32:121-30. (Correspondence) (Review)
553. Chen CJ, Yeoh SC, Yeh HT, Hsiao SM, Kuo HC. Surgical results in women with detrusor underactivity and stress urinary incontinence undergoing suburethral sling procedure – predictive factors for successful outcome. *Low Urin Tract Symptoms* 2020; 12:143-9. (Correspondence)
554. Yeh TC, Chen PC, Su YR, Kuo HC. Effect of botulinum toxin A on bladder pain—molecular evidence and animal studies. *Toxins (Basel)* 2020; 12: E98. (Correspondence) (Review)
555. Wang CC, Jiang YH, Kuo HC. The pharmacological mechanism of diabetes mellitus-associated overactive bladder and its treatment with botulinum toxin A. *Toxins (Basel)* 2020; 12:186. (Correspondence) (Review)
556. Chen LC, Kuo HC. Current management of refractory overactive bladder. *Low Urin Tract Symptoms* 2020; 12:109-16. (Correspondence) (Review)
557. Jiang YH, Yu WR, Kuo HC. Therapeutic effect of botulinum toxin A on sensory bladder disorders – from bench to bedside. *Toxins (Basel)* 2020; 12:166. (Correspondence) (Review)
558. Jiang YH, Jhang JF, Hsu YH, Ho HC, Wu YH, Kuo HC. Urine cytokines as biomarkers for diagnosing interstitial cystitis/ bladder pain syndrome and mapping its clinical characteristics. *Am J Physiol Renal Physiol* 2020; 318: F1391-9. (Correspondence)
559. Jiang YH, Chen SF, Kuo HC. Frontiers in the clinical applications of botulinum toxin A as treatment for neurogenic lower urinary tract dysfunction. *Int Neurourol J* 2020; 24:301-12. (Correspondence) (Review)
560. Ong HL, Lee CL, Kuo HC. Female bladder neck dysfunction - a videourodynamic diagnosis among women with voiding dysfunction. *Low Urin Tract Symptoms* 2020; 12:278-84. (Correspondence)
561. Homma Y, Akiyama Y, Tomoe H, Furuta A, Ueda T, Maeda D, Lin AT, Kuo HC, Lee MH, Oh SJ, Kim JC, Lee KS. Clinical guidelines for interstitial cystitis/bladder pain syndrome. *Int J Urol* 2020; 27:578-89.
562. Chow PM, Hsiao SM, Kuo HC. Obstructive patterns in videourodynamic studies predict responses of female dysfunctional voiding treated with or without urethral botulinum toxin injection: A long-term follow-up study. *Int Urogynecol J* 2020; 31:2557-64. (Correspondence).
563. Chuang YC, Meng E, Chancellor MB, Kuo HC. Pain reduction realized with extracorporeal shock wave therapy for the treatment of symptoms associated prospective, multicenter, randomized, double-blind, placebo-controlled study. *Neurourol Urodyn* 2020; 39:1505-14. (Correspondence)
564. Jiang YH, Kuo YC, Jhang JF, Lee CH, Hsu YH, Ho HC, Kuo HC. Repeated intravesical injections of platelet-rich plasma improve symptoms and alter urinary functional proteins in patients with refractory interstitial cystitis. *Sci Rep* 2020; 10:15218. (Correspondence)

565. Kuo HC. Botulinum toxin paves the way for the treatment of functional lower urinary tract dysfunction. *Toxins (Basel)* 2020; 12:394. (Editorial)

## 2021

566. Jhang JF, Hsu YH, Jiang YH, Ho HC, Kuo HC. Clinical relevance of bladder histopathological findings and their impact on treatment outcomes among patients with interstitial cystitis/bladder pain syndrome: An investigation of the European Society for the Study of Interstitial Cystitis histopathological classification. *J Urol* 2021; 205:226-35. (Correspondence)

567. Chuang YC, Lin CC, Chow PM, Lien CS, Tsui KH, Chou CL, Lee HY, Meng E, Kuo HC. A double-blind, randomized, placebo-controlled, parallel study to evaluate the efficacy and safety of imidafenacin in patients with overactive bladder in Taiwan. *Low Urin Tract Symptoms* 2021; 13:108-117. (Correspondence)

568. Wang CC, Chou CL, Chuang YC, Lin CC, Hsu YC, Liao CH, Kuo HC. Effectiveness and safety of intradetrusor botulinum toxin A injection for neurogenic detrusor overactivity and overactive bladder patients in Taiwan – A phase IV prospective, observational, multiple-center study (RESTORE STUDY). *Toxins* 2021; 13:911. (Correspondence)

569. Chow PM, Hsiao SM, Kuo HC. Identifying occult bladder outlet obstruction in women with detrusor-underactivity-like urodynamic profiles. *Sci Rep* 2021; 11:23242. (Correspondence)

570. Ho HC, Hsu YH, Jhang JF, Jiang YH, Kuo HC. Ultrastructural changes in the underactive bladder. *Tzu Chi Med J* 2021; 33:345-9. (Correspondence) (Review)

571. Ke QS, Lee CL, Kuo HC. Recurrent urinary tract infection in women and overactive bladder - is there a relationship? *Tzu Chi Med J* 2021; 33:13-21. (Correspondence) (Review)

572. Jhang JF, Lin TY, Ho HC, Jiang YH, Hsu YH, Lori Birder, Kuo HC. Deficits of urothelial cell proliferation, cytoskeleton, and barrier function protein expressions in patients with recurrent and persistent urinary tract infections. *Low Urin Tract Symptoms* 2021; 13:203-9. (Correspondence)

573. Jiang YH, Lee PJ, Kuo HC. Therapeutic efficacy of urethral sphincter injections of platelet-rich plasma for the treatment of stress urinary incontinence due to intrinsic sphincter deficiency - a proof of concept clinical trial. *Int Neurourol J* 2021; 25:51-8. (Correspondence)

574. Chen SF, Peng CH, Kuo HC. Will detrusor acontractility recover after medical or surgical treatment? A longitudinal long-term urodynamic follow-up. *Neurourol Urodyn* 2021; 40:228-36. (Correspondence)

575. Chuang FC, Yang TH, Kuo HC. Botulinum toxin A injection in the treatment of chronic pelvic pain with hypertonic pelvic floor in women: treatment techniques and results. *Low Urin Tract Symptoms* 2021; 13:5-12. (Correspondence) (Review)

576. Jiang YH, Jhang JF, Hsu YH, Ho HC, Lin TY, Lori Birder, Kuo HC. Urothelial health after platelet-rich plasma injection in intractable recurrent urinary tract infection: improved cell proliferation, cytoskeleton, and barrier function protein expression. *Low Urin Tract Symptoms* 2021; 13:271-8. (Correspondence)

577. Jiang YH, Jhang JF, Hsu YH, Ho HC, Wu YH, Kuo HC. Urine biomarkers in ESSIC type 2 interstitial cystitis/bladder pain syndrome and overactive bladder with developing a novel diagnostic algorithm. *Sci Rep* 2021; 11:914. (Correspondence)
578. Yu WR, Jhang JF, Ho HC, Jiang YH, Lee CL, Hsu YH, Kuo HC. Cystoscopic hydrodistention characteristics provide clinical and long-term prognostic features of interstitial cystitis after treatment. *Sci Rep* 2021; 11:455. (Correspondence)
579. Hsiao SM, Kuo HC. Predictors of further anti-incontinence interventions or transvaginal urethrolysis after a pubovaginal sling procedure in women with and without neurologic disorders. *J Formos Med Assoc* 2021; 120:1464-77. (Correspondence)
580. Jhang JF, Hsu YH, Ho HC, Jiang YH, Lee CL, Yu WR, Kuo HC. Possible association between bladder wall Morphological changes on computed tomography and bladder-centered interstitial cystitis/bladder pain syndrome. *Biomedicines* 2021; 9:1306. (Correspondence)
581. Chen SF, Kuo HC. Will repeated botulinum toxin A improve detrusor overactivity and bladder compliance in patients with chronic spinal cord injury? *Tzu Chi Med J* 2021; 33: 101-7. (Correspondence) (Review).
582. Lee YK, Jhang JF, Jiang YH, Hsu YH, Ho HC, Kuo HC. Difference in electron microscopic findings among interstitial cystitis/bladder pain syndrome with distinct clinical and cystoscopic characteristics. *Sci Rep* 2021; 11:17258. (Correspondence)
583. Jiang YH, Kuo HC. High percentage of neurologic deficits in the electrophysiology study of the lower urinary tract in patients with detrusor underactivity and chronic urinary retention. *Neurourol Urodyn* 2021; 40: 833-90. (Correspondence)
584. Yang HH, Jhang JF, Hsu YH, Jiang YH, Zhai WJ, Kuo HC. Smaller bladder capacity and stronger bladder contractility in patients with ketamine cystitis are associated with elevated TRPV1 and TRPV4. *Sci Rep* 2021; 11:5200. (Correspondence)
585. Lee PJ, Jiang YH, Kuo HC. A novel management for postprostatectomy urinary incontinence: platelet-rich plasma urethral sphincter injection. *Sci Rep* 2021; 11:5371. (Correspondence)
586. Jhang JF, Jiang YH, Hsu YH, Ho HC, Kuo HC. Decreased urothelial cytoskeleton and cell proliferation protein expression suggest interstitial cystitis/bladder pain syndrome patients with Hunner's lesion and grade 3 glomerulation might be different from the other type patients. *Int J Urol* 2021; 28:823-30. (Correspondence)
587. Wang CC, Lee CL, Hwang YT, Kuo HC. Adding mirabegron after intravesical onabotulinumtoxinA injection improves therapeutic effects in patients with refractory overactive bladder. *Low Urin Tract Symptoms* 2021; 13: 440-7. (Correspondence)
588. Yu WR, Chang WC, Kuo HC. Voiding dysfunctions in patients with non-Hunner's ulcer interstitial cystitis/ bladder pain syndrome do not affect long-term treatment outcome. *Int J Clin Pract* 2021; 75:e14372. (Correspondence)
589. Jhang JF, Kuo HC. Novel applications of non-invasive intravesical botulinum toxin A delivery in treatment of functional bladder disorders. *Toxins* 2021; 13:359. (Correspondence) (Review)

590. Jiang YH, Lee CL, Chen SF, Kuo HC. Therapeutic effects of urethral sphincter botulinum toxin A injection on dysfunctional voiding with different videourodynamic characteristics in non-neurogenic women. *Toxins* 2021; 13:362. (Correspondence)
591. Chiang CH, Jiang YH, Kuo HC. Therapeutic efficacy of biofeedback pelvic floor muscle exercise in women with dysfunctional voiding. *Sci Rep* 2021; 11:13757. (Correspondence)
592. Ou YC, Huang KH, Jan HC, Kuo HC, Kao YL, Tsai KJ. Therapeutic efficacy of urethral sphincteric botulinum toxin injections for female sphincter dysfunctions and a search for predictive factors. *Toxins* 2021; 13:398.
593. Kuo HC. Videourodynamic precision diagnosis and treatment of female lower urinary tract symptoms. *Urol Sci* 2021; 32:94-101. (Review)

## 2022

594. Jhang JF, Jiang YH, Hsu YH, Ho HC, Kuo HC. Pathogenesis evidence from human and animal models of detrusor underactivity. *Tzu Chi Med J* 2022; 34: 287-96. (Correspondence)
595. Kuo HC. How to choose appropriate medication for overactive bladder: Findings from the largest integrated clinical trial database analysis of mirabegron studies. *Tzu Chi Med J* 2022; 34:23-8. (Review)
596. Jiang YH, Jhang JF, Hsu YH, Ho HC, Kuo HC. Potential urine biomarkers in bladder outlet obstruction related detrusor underactivity. *Tzu Chi Med J* 2022; 34:388-93. (Correspondence) (Review)
597. Chiang CH, Chen SF, Kuo HC. Video-urodynamic characteristics of lower urinary tract dysfunctions in patients with chronic brain disorders. *Neurourol Urodyn* 2022; 41:255-63. (Correspondence)
598. Yeh HL, Kuo HC, Tsai CH, Lee RP. Reasons for altering bladder management and satisfaction with current bladder management in chronic spinal cord injury patients. *Int J Environ Res Public Health* 2022; 19:17032.
599. Jhang JF, Ho HC, Hsu YH, Jiang YH, Kuo HC. Bladder ultrastructure and urinary cytokine abnormality in patients with recurrent urinary tract infection and the changes after intravesical platelet-rich plasma injections. *Biomedicines* 2022; .10:245 (Correspondence)
600. Lee CL, Jhang JF, Ho HC, Hsu YH, Kuo HC. Therapeutic outcome of active management in male patients with detrusor underactivity based on clinical diagnosis and videourodynamic classification. *Sci Rep* 2022; 12:362. (Correspondence)
601. Wang HJ, Kuo HC. Effects of different urodynamic characteristics on therapeutic outcomes of overactive bladder medication in a real-life clinical practice. *Tzu Chi Med J* 2022; 34:441-7.
602. Kuo HC. Overexpression of HIF1 $\alpha$  in Hunner Lesions of Interstitial Cystitis: Pathophysiological Implications. *J Urol* 2022; 207:645. (Editorial Comment)
603. Kao YL, Ou YC, Tsai KJ, Kuo HC. Predictive factors for a successful treatment outcome in patients with different voiding dysfunction subtypes who received urethral sphincter botulinum injection. *Toxins* 2022; 14:877. (Correspondence)

604. Lee CL, Jhang JF, Jiang YH, Kuo HC. Real-world data regarding satisfaction to botulinum toxin A injection into the urethral sphincter and further bladder management for voiding dysfunction among patients with spinal cord injury and voiding dysfunction. *Toxins* 2022; 14:30. (Correspondence)
605. Chen SF, Jiang YH, Jhang JF, Kuo HC. Satisfaction with detrusor onabotulinumtoxinA injections and conversion to other bladder management in patients with chronic spinal cord injury. *Toxins* 2022; 14:35. (Correspondence)
606. Lin CC, Kuo HC. Video-urodynamic characteristics and predictors of switching from botulinum neurotoxin A injection to augmentation enterocystoplasty in spinal cord injury patients. *Toxins* 2022; 14:47. (Correspondence)
607. Wu SY, Jiang YH, Jhang JF, Hsu YH, Ho HC, Kuo HC. Inflammation and barrier function deficits in the bladder urothelium of patients with chronic spinal cord injury and recurrent urinary tract infections. *Biomedicines* 2022; 10:220. (Correspondence)
608. Chiang CH, Kuo HC. The efficacy and mid-term durability of urethral sphincter injections of platelet-rich plasma in treatment of female stress urinary incontinence. *Frontiers Pharmacol* 2022;13: 847520. (Correspondence)
609. Jhang JF, Jiang YH, Hsu YH, Ho HC, Lori Birder, Lin TY, Kuo HC. Improved urothelial cell proliferation, cytoskeleton and barrier function protein expression in the patients with interstitial cystitis/bladder pain syndrome after intravesical platelet-rich plasma injection. *Int Neurourol J* 2022; 26(Suppl 1):S57-67. (Correspondence)
610. Jiang YH, Jhang JF, Lee YK, Kuo HC. Low-energy shock wave plus intravesical instillation of botulinum toxin A for interstitial cystitis/bladder pain syndrome: Pathophysiology and preliminary result of a novel minimally invasive treatment. *Biomedicines* 2022; 10:396. (Correspondence)
611. Chen SF, Kuo HC. Interventional management and surgery of neurogenic lower urinary tract dysfunction in patients with chronic spinal cord injury: A Urologist's perspective. *Low Urin Tract Symptoms* 2022; 14:132-9. (Correspondence)
612. Lee CL, Chen SF, Jiang YH, Kuo HC. Effect of videourodynamic subtypes on treatment outcomes of female dysfunctional voiding. *Int Urogynecol J* 2022; 33:1283-91. (Correspondence)
613. Jiang YH, Jhang JF, Lin TY, Ho HC, Hsu YH, Kuo HC. Therapeutic efficacy of intravesical platelet-rich plasma injections for interstitial cystitis/bladder pain syndrome – a comparative study of different injection number, additives and concentrations. *Front Pharmacol* 2022; 13:853776. (Correspondence)
614. Chen SF, Jhang JF, Jiang YH, Kuo HC. Treatment outcomes of detrusor underactivity in women based on clinical and videourodynamic characteristics. *Int Urol Nephrol* 2022; 54:1215-23. (Correspondence)
615. Chen SF, Chuang YC, Wang CC, Liao CH, Kuo HC. Therapeutic efficacy and adverse events of overactive bladder medication on patients with central nervous system disorders - A multicenter clinical study. *J Formos Med Assoc* 2022; 121:2101-8. (Correspondence)

616. Jiang YH, Jhang JF, Ho HC, Hsu YH, Kuo HC. Diagnostic and prognostic value of urine biomarkers in women with dysfunctional voiding. *Sci Rep* 2022; 12:6608. (Correspondence)
617. Jiang YH, Jhang JF, Kuo HC. Can we use urinary cytokine/chemokine analysis in discriminating ulcer-type interstitial cystitis/bladder pain syndrome? *Diagnostics* 2022; 12:1093. (Correspondence)
618. Jhang JF, Ho HC, Jiang YH, Hsu YH, Kuo HC. Clinical correlation of bladder electron microscopic characteristics in patients with detrusor underactivity of various etiologies. *Biomedicines* 2022; 10:1055. (Correspondence)
619. Kao YL, Ou YC, Kuo HC. Bladder dysfunction in older adults: The botulinum toxin option. *Drugs Ageing* 2022; 39:401-6. (Correspondence) (Review)
620. Yu WR, Kuo HC. Usefulness of videourodynamic study in the decision-making of surgical intervention and bladder management for neurogenic lower urinary tract dysfunction among patients with myelomeningocele. *Int Urol Nephrol* 2022; 54: 1815-24.
621. Yu WR, Jiang YH, Jhang JF, Kuo HC. Use of urinary cytokine and chemokine levels for identifying bladder conditions and predicting treatment outcomes in patients with interstitial cystitis/bladder pain syndrome. *Biomedicines* 2022; 10:1149. (Correspondence)
622. Lee YK, Jiang YH, Jhang JF, Han-Chen Ho, Kuo HC. Changes in the ultrastructure of the bladder urothelium in patients with interstitial cystitis after intravesical injections of platelet-rich plasma. *Biomedicines* 2022; 10:1182. (Correspondence)
623. Chow PM, Kuo HC. Performance of urinary biomarkers in differentiating dysfunctional voiding in women with overactive bladder syndrome: A prospective pilot study. *Int Urol Nephrol* 2022; 54(10):2497-502. (Correspondence)
624. Chang TL, Chen SF, Kuo HC. Surgical outcomes of male patients with chronic central nervous system disorders and voiding dysfunction due to bladder outlet obstruction. *Int Urol Nephrol* 2022; 54:2511-9. (Correspondence)
625. Yu WR, Chang WC, Kuo HC. Clinical presentation, videourodynamic characteristics, and treatment outcome in men with interstitial cystitis-like lower urinary tract symptoms. *Int Urol Nephrol* 2022; 54:2157-65.
626. Jiang YH, Jhang JF, Ho HC, Chiou DY, Kuo HC. Urine oxidative stress biomarkers as novel biomarkers in interstitial cystitis/bladder pain syndrome. *Biomedicines* 2022; 10:1701. (Correspondence)
627. Kuo HC. Clinical application of botulinum neurotoxin in lower-urinary-tract diseases and dysfunctions: Where are we now and what more can we do? *Toxins* 2022; 14:498. (Review)
628. Yu WR, Chuang FC, Chang WC, Kuo HC. Pelvic floor myofascial pain might influence treatment outcome with interstitial cystitis/ bladder pain syndrome. *Pain Physician* 2022; 25: E1315-22. (Correspondence)
629. Lee PJ, Jiang YH, Kuo HC. Therapeutic efficacy and mid-term durability of urethral sphincter platelet-rich plasma injections to treat postprostatectomy stress urinary incontinence. *Biomedicines* 2022; 10:2235. (Correspondence)

630. Jhang JF, Jiang YH, Kuo HC. Current understanding of the pathophysiology and novel treatments of interstitial cystitis/bladder pain syndrome. *Biomedicines* 2022; 10:2380. (Review)
631. Kuo HC. A precision urodynamic diagnosis is essential for A successful treatment in functional lower urinary tract dysfunction. *Eur Urol Open Sci* 2022; 46:36-8. (Editorial)
632. Chen SF, Lee YK, Kuo HC. Satisfaction with urinary incontinence treatments in patients with chronic spinal cord injury. *J Clin Med* 2022; 11:5864. (Correspondence)
633. Jiang YH, Jhang JF, Hsu YH, Kuo HC. Usefulness of urinary biomarkers for assessing bladder condition and histopathology in patients with interstitial cystitis/bladder pain syndrome. *Int J Mol Sci* 2022; 23:12044. (Correspondence)
634. Yu WR, Jhang JF, Chen BY, Ou SR, Lee HM, Kuo HC. Multimodal treatment with cognitive-behavioral therapeutic intervention plus bladder treatment as more effective than monotherapy for patients with interstitial cystitis / bladder pain syndrome. *J Clin Med* 2022; 11:6221. (Correspondence)
635. Wu SY, Kuo HC. Satisfaction with surgical procedures and bladder management of chronic spinal cord injured patients with voiding dysfunction who desire spontaneous voiding. *J Pers Med* 2022; 12:1751. (Correspondence)
636. Wang CC, Lee MH, Chuang YC, Juan YS, Lee HY, Lin WY, Liao CH, Kuo HC. First reported study of daily, high dose transdermal application of oxybutynin in a humid country. *Continence* 202; 4:1005182 (Correspondence)
637. Chen YC, Ou YC, Hu JC, Yang MH, Lin WY, Huang SW, Lin WY, Lin CC, Victor C. Lin, Chuang YC, Kuo HC on behalf of the Taiwan Continence Society Spinal Cord Injury Study Group. Bladder management strategies for urological complications in patients with chronic spinal cord injury. *J Clin Med* 2022; 11:6850. (Correspondence)
638. Peng CH, Chen SF, Kuo HC. Long-term follow-up of lower urinary tract outcome in children with dysfunctional voiding. *J Clin Med* 2022; 11:7395. (Correspondence)
639. Hung FC, Kuo HC. Liposome-encapsulated botulinum toxin A in treatment of functional bladder disorders. *Toxins* 2022; 14:838. (Correspondence) (Review)
640. Wu SY, Jhang JF, Liu HH, Chen JT, Li JR, Chiu B, Chen SL, Kuo HC. Long-term surveillance and management of urological complications in chronic spinal cord injured patients. *J Clin Med* 2022; 11:7307. (Correspondence) (Review)
641. Yu WR, Jiang YH, Jhang JF, Chang WC, Kuo HC. Treatment outcomes of intravesical botulinum toxin A injections on patients with interstitial cystitis/bladder pain syndrome. *Toxins* 2022; 14:871. (Correspondence)

## 2023

642. Chen WH, Jiang YH, Kuo HC. Urinary oxidative stress biomarkers in the diagnosis of detrusor overactivity in female patients with stress urinary incontinence. *Biomedicines* 2023; 11:357. (Correspondence)

643. Jiang YH, Jhang JF, Kuo HC. The clinical application of intravesical botulinum toxin A injection in patients with overactive bladder and interstitial cystitis. *Tzu Chi Med J* 2023; 35:31-7. (Correspondence) (Review)
644. Chow PM, Kuo HC. Botulinum toxin A injection for autonomic dysreflexia - Detrusor injection or urethral sphincter injection? *Toxins* 2023; 15:108. (Correspondence)
645. Kuo YC, Kuo HC. Comparative study of different combinations of mirabegron and antimuscarinics in treatment for overactive bladder syndrome in elderly. *Tzu Chi Med J* 2023; 35:62-8. (Correspondence)
646. Jiang YH, Jhang JF, Birder LA, Kuo HC. Sensory receptor, inflammatory, and apoptotic protein expression in the bladder urothelium of patients with different subtypes of interstitial cystitis/bladder pain syndrome. *Int J Mol Sci* 2023; 24:820. (Correspondence)
647. Chen SF, Kuo HC. Urethral sphincter botulinum Toxin A injection for non-spinal cord injured patients with voiding dysfunction without anatomical obstructions: Which patients benefit most? *Toxins* 2023; 15:87. (Correspondence)
648. Jhang JF, Liu CD, Hsu YH, Chen CC, Chen HC, Jiang YH, Wu WC, Peng CW, Kuo HC. EBV infection mediated BDNF expression is associated with bladder inflammation in interstitial cystitis/bladder pain syndrome with Hunner's lesion. *J Pathol* 2023; 259:276-90. (Correspondence)
649. Chen YJ, Lo SH, Meng E, Shen JD, Eric Chou CL, Chen SF, Lee MH, Hsu CY, Ong HL, Chen JT, Chen SL, Tsai YA, Lin CC, Wu SY, Chiu B, Kuo HC, and Taiwan Continence Society Spinal Cord Injury Study Group. Clinical guidelines of patient-centered bladder management of neurogenic lower urinary tract dysfunction due to chronic spinal cord injury—Part 1: Pathophysiology, treatment strategy and priority. *Urol Sci* 2023; 34:3-9. (Correspondence) (Review)
650. Kao YL, Chen JT, Chen SL, Shao IH, Wang CC, Chiang IN, Hsu YC, Lee KH, Lee WC, Yeh TC, Kuo YC, Chiang BJ, Liao CH, Chen PC, Meng E, Lee YC, Kuo HC, and Taiwan Continence Society Spinal Cord Injury Study Group. Clinical guidelines of patient-centered bladder management of neurogenic lower urinary tract dysfunction due to chronic spinal cord injury — Part 2: Conservative and minimally invasive treatment. *Urol Sci* 2023; 34:10-7. (Correspondence) (Review)
651. Chang TL, Kuo HC. The videourodynamic characteristics of patients with chronic spinal cord injury with different injury levels and bladder conditions. *Urol Sci* 2023; 34:46-52. (Correspondence)
652. Lin YH, Fan YH, Wu CT, Shen YC, Hu JC, Huang SW, Chow PM, Chang PC, Liao CH, Chen YC, Victor C. Lin, Hsu CC, Chang SJ, Wang CC, Lin WY, Lin CC, Jiang YH, Kuo HC, and Taiwan Continence Society Spinal Cord Injury Study Group. Clinical guidelines of patient-centered bladder management of neurogenic lower urinary tract dysfunction due to chronic spinal cord injury – Part 3: Surgical treatment in chronic spinal cord injured patients. *Urol Sci* 2023; 34:109-16. (Correspondence) (Review)
653. Ou YC, Kao YL, Ho YH, Wu KY, Kuo HC. Intravesical injection of botulinum toxin type A in patients with refractory overactive bladder - Results between young and elderly populations, and factors associated with unfavorable outcomes. *Toxins* 2023; 13:95. (Correspondence)

654. Kuo HC. Bladder outlet surgery is effective only in patients with central nervous system disorders and voiding dysfunction proven to be obstructed. *Int Urol Nephrol* 2023; 55:1157. (Letter to the Editor)
655. Jhang JF, Yu WR, Kuo HC. Comparison of the clinical efficacy and adverse events between intravesical injections of platelet-rich plasma and botulinum toxin A for the treatment of interstitial cystitis refractory to conventional treatment. *Toxins* 2023; 15:121. (Correspondence)
656. Ong HL, Kuo HC. Transurethral incision of the bladder neck with additional procedure resumes spontaneous voiding in female voiding dysfunction - A long-term follow-up. *J Clin Med* 2023; 12:1514. (Correspondence)
657. Chen WH, Lee YK, Kuo HC, Wang JH, Jiang YH. Oncological and functional outcomes of high-risk and very high-risk prostate cancer patients after robot-assisted radical prostatectomy. *PLoS ONE* 2023; 18: e0282494.
658. Jhang JF, Jiang YH, Kuo HC. Discriminating different overactive bladder subtypes by urinary biomarkers in women with frequency–urgency syndrome. *Biomedicines* 2023; 11:673. (Correspondence)
659. Fan YH, Shen YC, Hsu CC, Chow PM, Chang PC, Lin YH, Chang SJ, Jiang YH, Liao CH, Wang CC, Wu CT, Kuo HC. Current surgical treatment for neurogenic lower urinary tract dysfunction in patients with chronic spinal cord injury. *J Clin Med* 2023; 12:1400. (Correspondence) (Review)
660. Ong HL, Chiang IN, Hsu LN, Chin CW, Shao IH, Jang MY, Juan YS, Wang CC, Kuo HC. Conservative bladder management and medical treatment in chronic spinal cord injury patients. *J Clin Med* 2023; 12:2021. (Correspondence) (Review)
661. Lee HY, Kuo HC. Intravesical injection of botulinum toxin in men without bladder outlet obstruction and post deobstructive prostate surgery. *Toxins* 2023; 15:221. (Correspondence) (Review)
662. Jiang YH, Jhang JF, Kuo HC. Urinary oxidative stress biomarker levels might be useful to identify functional bladder disorders in women with frequency and urgency syndrome. *J Clin Med* 2023; 12:2336. (Correspondence)
663. Fan YH, Kuo HC. Efficacy of intravesical botulinum toxin A injection in the treatment of refractory overactive bladder in children. *J Pres Med* 2023; 13:616. (Correspondence)
664. Hsu LN, Jhang JF, Ou YC, Chuang YC, Jang MY, Chin CW, Juan YS, Yang MH, Lin WY, Liu HH, Li JR, Kuo HC, and Taiwan Continence Society Spinal Cord Injury Study Group. Clinical guidelines of patient-centered bladder management of neurogenic lower urinary tract dysfunction due to chronic spinal cord injury – Part 4: Patient Risk, Bladder Management, and Active Surveillance. *Urol Sci* 2023; 34:170-5. (Correspondence) (Review)
665. Chen PC, Lee KH, Lee WC, Yeh TC, Chiang BJ, Liao CH, Meng En, Kao YL, Lee YC, Kuo HC. Treating neurogenic lower urinary tract dysfunction in chronic spinal cord injury patients – When intravesical Botox injection or urethral Botox injection? *Toxins* 2023; 5:288. (Correspondence) (Review)
666. Jiang YH, Jhang JF, Wu YH, Kuo HC. Investigating urine biomarkers in detrusor underactivity, and detrusor overactivity with detrusor underactivity patients. *Biomedicine* 2023; 11:1191. (Correspondence)
667. Ho GR, Wei CW, Kuo HC. Voiding dysfunction due to urethral sphincter dysfunction might be an early neurological presentation of central nervous system disorders in aged patients. *J Pers Med* 2023; 3:693. (Correspondence)

668. Kuo HC. Botulinum toxin brings a light to the shadow of functional urology. *Toxins* 2023; 15:321. (Editorial)
669. Jhang JF, Birder LA, Kuo HC. Pathophysiology, clinical presentation, and management of ketamine-induced cystitis. *Tzu Chi Med J* 2023; 35:205-212 (Correspondence) (Review)
670. Lee YK, Kuo HC. Effectiveness of platelet-rich plasma injections as prophylaxis for recurrent urinary tract infection in women. *J Clin Med* 2023; 12:4129. (Correspondence)
671. Lee CL, Kuo HC. Treating overactive bladder symptoms after transurethral prostatic surgery for benign prostatic hyperplasia - Which medication to choose? *Tzu Chi Med J* 2023; 35:312-6. (Correspondence)
672. Lee PJ, Kuo HC. Low detrusor contractility has a less favorable outcome of anti-incontinence surgery for women with stress urinary incontinence. *Int Urol Nephrol* 2023; 55:2789-98. (Correspondence)
673. Yu WR, Jiang YH, Jhang JF, Kuo HC. Use of urinary biomarkers in discriminating interstitial cystitis/ bladder pain syndrome from male lower urinary tract dysfunctions. *Int J Mol Sci* 2023; 24:12055. (Correspondence)
674. Yu WR, Jiang YH, Jhang JF, Kuo HC. Bladder pain syndrome associated with interstitial cystitis: Recent research and treatment options. *Curr Bladder Dysfunct Rep* 2023; 18:389-400. (Correspondence) (Review)
675. Chiang CH, Jiang YH, Kuo HC. Efficacy of single and repeated transurethral bladder neck incisions for female voiding dysfunction. *World J Urol* 2023; 41:2809-15. (Correspondence)
676. Kuo HC. Intravesical injections of autologous platelet-rich plasma for the treatment of refractory interstitial cystitis. *Low Urin Tract Symptoms* 2023; 15:210-5.
677. Lin CC, Kuo HC, Li JR, Chuang YC. Comparative study between behavior therapy and behavior therapy plus mirabegron 50 mg in sexually active men with bothersome overactive bladder symptoms – A multicenter, randomized study. *Int Neurol J* 2023; 27:182-91.
678. Jhang JF, Kuo HC. The role of viral infection in the pathogenesis of interstitial cystitis/bladder pain syndrome. *Curr Bladder Dysfunct Rep* 2023; 18:374-80. (Correspondence) (Review)
679. Chen YC, Chen HW, Kuo HC. Bladder neck incompetence could be an etiology of overactive bladder syndrome in women with stress urinary incontinence after anti-incontinence surgery - insights from transrectal sonography. *World J Urol* 2023; 41:3083-9. (Correspondence)
680. Jiang YH, Kuo HC. Current optimal pharmacologic therapies for overactive bladder. *Exp Opin Pharmacother* 2023; 24:2005-19. (Correspondence) (Review)
681. Hung FC, Kuo HC. Management of patients with detrusor hyperactivity with impaired contractility. *Curr Bladder Dysfunct Rep* 2023; 18:280-4. (Correspondence) (Review)

## 2024

682. Yu WR, Jiang YH, Jhang JF, Kuo HC. Cystoscopic characteristic findings of interstitial cystitis and clinical implications. *Tzu Chi Med J* 2024; 36:30-7. (Correspondence) (Review)
683. Chen SF, Kuo HC. Management of spinal cord injury patients with neurogenic lower urinary tract dysfunction using minimally invasive and surgical therapies in Taiwan. *Int Urol Nephrol* 2024; 56:1205-16. (Correspondence)
684. Yu WR, Kuo HC. Multimodal therapies and strategies for the treatment of interstitial cystitis/bladder pain syndrome. *Low Urin Tract Symptoms* 2024; 16: e12508. (Correspondence)
685. Jhang JF, Jiang YH, Lin TY, Kuo HC. The tumor necrosis factor- $\alpha$  level in platelet-rich plasma (PRP) might be associated with treatment outcome in the patients with interstitial cystitis/bladder pain syndrome or recurrent urinary tract infection who underwent intravesical PRP injections. *Int J Mol Sci* 2024; 25:163. (Correspondence)

686. Jhang JF, Yu WR, Huang WT, Kuo HC. Combination of urinary biomarkers and machine learning models provided a higher predictive accuracy to predict long-term treatment outcomes of patients with interstitial cystitis/bladder pain syndrome. *World J Urol* 2024. (Correspondence) (Accept-2024.01.25)
687. Yu WR, Jhang JF, Kuo HC. Intravesical botulinum toxin injection plus hydrodistention is more effective in patients with bladder pain predominant interstitial cystitis / bladder pain syndrome. *Toxins* 2024; 16:74. (Correspondence)
688. Jiang YH, Liu YS, Wei YC, Jhang JF, Kuo HC, Huang HH, Chan WY, Lin GL, Cheng WC, Lin SC, Wang HJ. Hypermethylation loci of ZNF671, IRF8, and OTX1 as potential urine-based predictive biomarkers for bladder cancer. *Diagnostics* 2024; 14:468.
689. Kuo HC, Peng CW, Jiang YH, Jhang JF. Urinary viral spectrum in patients with interstitial cystitis/bladder pain syndrome and the clinical efficacy of valacyclovir treatment. *Biomedicines* 2024; 12:522.
690. Jiang YH, Jhang JF, Chen SF, Kuo HC. Real-life treatment outcome of botulinum toxin A injection on overactive bladder and voiding dysfunction in patients with central nervous system lesions. *Toxins* 2024; 16:123. (Correspondence)
691. Oh SJ, Cho ST, Kuo HC, Chou CL, Hsu YC, Lee KS, Hadi F, Song Y. Treatment patterns with mirabegron and antimuscarinics for overactive bladder: A prospective, registry study in Taiwan and South Korea (FAITH). *Adv Ther* 2024; 41:1652-71.
692. Yu WR, Jiang YH, Jhang JF, Kuo HC. Urine biomarker could be a useful tool for differential diagnosis of a lower urinary tract dysfunction. *Tzu Chi Med J* 2024; 36:110-9. (Correspondence) (Review)
693. Kuo HC. Lower urinary tract dysfunction in the central nervous system neurogenic bladder and the real-life treatment outcome of botulinum toxin A. *Tzu Chi Med J* 2024. (Review) (Accept-2024.03.25)